2024/11/05 更新

写真a

マエダ ケイコ
前田 啓子
MAEDA Keiko
所属
医学部附属病院 消化器内科 助教
大学院担当
大学院医学系研究科
職名
助教

学位 1

  1. 博士(医学) ( 2016年4月   名古屋大学 ) 

研究分野 2

  1. ライフサイエンス / 消化器内科学

  2. ライフサイエンス / 消化器内科学

経歴 2

  1. 名古屋大学医学部附属病院

    2018年4月 - 現在

      詳細を見る

    国名:日本国

  2. Boston Children's Hospital

    2016年6月 - 2018年3月

所属学協会 4

  1. 日本内科学会

  2. 日本消化器内視鏡学会

  3. 日本消化器病学会

  4. 日本炎症性腸疾患学会

受賞 5

  1. 学術奨励賞

    2023年6月   日本女医会  

  2. 日本炎症性腸疾患学会-アッヴィ研究奨励賞

    2023年2月   日本炎症性腸疾患学会  

  3. 令和4年度 医学系研究科医学奨励賞 最優秀賞

    2023年1月   名古屋大学  

  4. Early career investigator award

    2018年6月  

     詳細を見る

    受賞区分:国際学会・会議・シンポジウム等の賞  受賞国:アメリカ合衆国

  5. Poster of distinction award

    2017年5月   アメリカ消化器病学会  

     詳細を見る

    受賞区分:国内外の国際的学術賞  受賞国:アメリカ合衆国

 

論文 86

  1. Initial Tumor Size and Narrow-Band Image Findings Estimate Growth Speed in Duodenal Tumors. 査読有り 国際誌

    Hirose T, Kakushima N, Minami Y, Furune S, Ishikawa E, Sawada T, Maeda K, Yamamura T, Furukawa K, Nakamura M, Nakaguro M, Kawashima H

    Digestive diseases (Basel, Switzerland)     頁: 1 - 10   2024年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1159/000540544

    PubMed

  2. Artificial intelligence-based diagnostic imaging system with virtual enteroscopy and virtual unfolded views to evaluate small bowel lesions in Crohn's disease. 査読有り 国際誌

    Furukawa K, Oda M, Watanabe O, Nakamura M, Yamamura T, Maeda K, Mori K, Kawashima H

    Revista espanola de enfermedades digestivas     2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.17235/reed.2024.10405/2024

    PubMed

  3. Reply: Interleukin-18 Inhibition in Inflammatory Bowel Diseases: A Delicate Balance.

    Maeda K, Kawashima H

    Inflammatory bowel diseases     2024年3月

     詳細を見る

    記述言語:英語  

    DOI: 10.1093/ibd/izae039

    PubMed

  4. Risk factors for rebleeding in gastroduodenal ulcers 国際誌

    Ito, N; Funasaka, K; Fujiyoshi, T; Nishida, K; Satta, Y; Furukawa, K; Kakushima, N; Furune, S; Ishikawa, E; Mizutani, Y; Sawada, T; Maeda, K; Ishikawa, T; Yamamura, T; Ohno, E; Nakamura, M; Miyahara, R; Sasaki, Y; Haruta, JI; Fujishiro, M; Kawashima, H

    IRISH JOURNAL OF MEDICAL SCIENCE   193 巻 ( 1 ) 頁: 173 - 179   2024年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Irish Journal of Medical Science  

    Background: Rebleeding after hemostasis of the gastroduodenal ulcer (GDU) is one of the indicators associated with death among GDU patients. However, there are few studies on risk score that contribute to rebleeding after endoscopic hemostasis of bleeding peptic ulcers. Aims: The aim of this study was to identify factors associated with rebleeding, including patient factors, after endoscopic hemostasis of bleeding gastroduodenal ulcers and to stratify the risk of rebleeding. Methods: We retrospectively enrolled 587 consecutive patients who were treated for Forrest Ia to IIa bleeding gastroduodenal ulcers with endoscopic hemostasis at three institutions. Risk factors associated with rebleeding were assessed using univariate and multivariate logistic regression analyses. The Rebleeding Nagoya University (Rebleeding-N) scoring system was developed based on the extracted factors. The Rebleeding-N score was internally validated using bootstrap resampling methods. Results: Sixty-four patients (11%) had rebleeding after hemostasis of gastroduodenal ulcers. Multivariate logistic regression analysis revealed four independent rebleeding risk factors: blood transfusion, albumin <2.5, duodenal ulcer, and diameter of the exposed vessel ≧2 mm. Patients with 4 risk factors in the Rebleeding-N score had a 54% rebleeding rate, and patients with 3 risk factors had 44% and 25% rebleeding rates. In the internal validation, the mean area under the curve of the Rebleeding-N score was 0.830 (95% CI = 0.786–0.870). Conclusions: Rebleeding after clip hemostasis of bleeding gastroduodenal ulcers was associated with blood transfusion, albumin <2.5, diameter of the exposed vessel ≧2 mm, and duodenal ulcer. The Rebleeding-N score was able to stratify the risk of rebleeding.

    DOI: 10.1007/s11845-023-03450-2

    Web of Science

    Scopus

    PubMed

  5. COLITIS CYSTICA PROFUNDA DIAGNOSED BY ESD

    Yamada K., Yamamura T., Nakamura M., Maeda K., Sawada T., Ishikawa E., Kajikawa G., Hasegawa I., Yokoi T., Kawashima H.

    Gastroenterological Endoscopy   66 巻 ( 3 ) 頁: 279 - 285   2024年

     詳細を見る

    記述言語:日本語   出版者・発行元:Gastroenterological Endoscopy  

    A 46-year-old female patient presented to our hospital for close examination and treatment after a rectal mass was observed during a CS performed at another hospital. On repeat CS, we observed a 10-mm, submucosal, tumor-like mass in the lower rectum. EUS showed a 10-mm hypoechoic tumor located in the submucosa. We performed ESD because the boring biopsy specimens showed nonspecific pathologic findings. Pathological examination of the resected lesion confirmed the diagnosis of colitis cystica profunda.

    DOI: 10.11280/gee.66.279

    Scopus

    CiNii Research

  6. Analysis of Neuropeptides in the Intestinal Mucus of Patients with Ulcerative Colitis Using RNA Sequencing. 査読有り 国際誌

    Nakamura M, Murate K, Maeda K, Yamamura T, Sawada T, Ishikawa E, Furukawa K, Hirose T, Uetsuki K, Iida T, Mizutani Y, Yamao K, Ishizu Y, Ishikawa T, Honda T, Kawashima H

    Digestion   105 巻 ( 5 ) 頁: 400 - 410   2024年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Digestion  

    Introduction: Inflammation in ulcerative colitis (UC) originates in the colorectal mucosa. Transcriptome sequencing analysis of the colorectal mucosa allows the identification of potential neuropeptides related to local neurotransmission. The intestinal mucus lining the surface of the mucosa may harbor biomarkers of mucosal inflammation; however, this has not been sufficiently investigated, given the difficulty in obtaining human samples. We previously reported the feasibility of obtaining mucin samples for proteomic analysis by brushing during colonoscopy. Herein, we aimed to investigate the composition of the intestinal mucus and detect neuropeptides characteristic of UC. Methods: Mucus and mucosal samples were collected from patients with UC from the colorectum in areas showing remission or active UC using a brush catheter and biopsy forceps during colonoscopy. RNA sequencing findings of mucus samples of active and remission areas were compared. RNA and protein expression levels of significantly upregulated neuropeptides were analyzed. Results: Of the neuropeptides associated with UC, somatostatin (SST) was significantly elevated in areas of remission, according to RNA sequencing results of mucus and expression levels in mucus RNA and proteins. Conversely, SST expression in the mucosa was increased in the inflamed areas. Flow cytometry revealed that the fluorescence intensity of SST-positive cells in the remission zone was higher in the mucus than in the mucosa. Conclusion: SST expression in the mucus is considered to be an important factor associated with UC activity.

    DOI: 10.1159/000540052

    Scopus

    PubMed

  7. A CASE OF INTRA-ABDOMINAL HAEMORRHAGE AFTER COLD SNARE POLYPECTOMY FOR COLORECTAL POLYPS

    Ikegami S., Yamamura T., Nakamura M., Maeda K., Sawada T., Ishikawa E., Yamashita A., Kawamura T., Yokoi T., Kawashima H.

    Gastroenterological Endoscopy   66 巻 ( 5 ) 頁: 1236 - 1241   2024年

     詳細を見る

    記述言語:日本語   出版者・発行元:Gastroenterological Endoscopy  

    A 51-year-old man underwent colonoscopy for endoscopic resection of polyps which were detected by CT colonography. Cold Snare Polypectomy (CSP) was performed for resection of an adenomatous polyp present in the splenic flexure. Two hours after the endoscopy, the patient experienced a sudden epigastric pain. Abdominal CT showed a mass-like thickening of the colon wall at the splenic flexure, leakage of contrast medium from the blood vessels in the wall, and hemorrhagic ascites in the abdominal cavity. The patient was diagnosed with intra-abdominal hemorrhage post a CSP procedure and underwent partial resection of the transverse colon through transverse colostomy. The surgical specimen showed a marked hematoma in the muscle layer below the site of CSP; however, no perforation was evident.

    DOI: 10.11280/gee.66.1236

    Scopus

    CiNii Research

  8. Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis.

    Uchida G, Nakamura M, Yamamura T, Maeda K, Sawada T, Ishikawa E, Furukawa K, Iida T, Mizutani Y, Yamao K, Ishikawa T, Ishizu Y, Honda T, Ishigami M, Kawashima H

    Inflammatory intestinal diseases   8 巻 ( 2 ) 頁: 60 - 68   2023年10月

     詳細を見る

    記述言語:英語   出版者・発行元:Inflammatory Intestinal Diseases  

    Introduction: Ustekinumab (UST) has been approved for the treatment of moderate-to-severe ulcerative colitis (UC). Real-world data showing the effectiveness and safety of UST are necessary to confirm the results of clinical trials for applicability in daily clinical practice. Although some studies have reported real-world evidence of UST, only few studies have confirmed its effectiveness in the real world. The aim of this study was to assess the short- and long-term effectiveness, durability, safety, and risk factors for discontinuation of UST in UC in clinical practice. Methods: This was a retrospective, single-center, observational study. From March 2020 to January 2023, all consecutive patients with active UC who were treated with UST at Nagoya University Hospital were included. The primary outcome was the clinical remission rate at weeks 2-8 and weeks 24-48. The secondary outcomes included clinical response, persistence of UST therapy, endoscopic changes during follow-up, risk factors for UST discontinuation, and occurrence of any adverse events. The clinical effectiveness was evaluated using the Lichtiger score. Results: A total of 31 patients were included in this study. The clinical remission rates were 9.7%, 29.0%, 54.8%, and 64.5% at weeks 2, 8, 24, and 48, respectively. Twelve (38.7%) patients discontinued UST during the follow-up period. The probability of continuing UST was 93.5%, 80.6%, 77%, and 70% at weeks 2, 8, 24, and 48, respectively. The major reason for discontinuation of UST was primary failure (75.0%). A high baseline C-reactive protein (CRP) level was a significant risk factor for the discontinuation of UST. No adverse events were observed in this study. Conclusion: UST is effective for patients with UC. High CRP levels were identified as a risk factor for UST discontinuation. The findings of this study would help clinicians to select appropriate treatment options for patients with UC by identifying the risk factors for treatment discontinuation.

    DOI: 10.1159/000531497

    Scopus

    PubMed

  9. Clinical characteristics of Dieulafoy's lesion in the small bowel diagnosed and treated by double-balloon endoscopy 査読有り 国際誌

    Nakamura, M; Yamamura, T; Maeda, K; Sawada, T; Ishikawa, E; Furukawa, K; Iida, T; Mizutani, Y; Yamao, K; Ishikawa, T; Honda, T; Ishigami, M; Kawashima, H

    BMC GASTROENTEROLOGY   23 巻 ( 1 ) 頁: 290 - 290   2023年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BMC Gastroenterology  

    Background: Obscure gastrointestinal bleeding refers to bleeding for which the source cannot be ascertained even through balloon-assisted endoscopy. In certain instances, Dieulafoy’s lesion in the small bowel is presumed to be the underlying cause. Aim: This retrospective study aimed to elucidate the clinical characteristics of Dieulafoy’s lesion in the small bowel as diagnosed via double-balloon endoscopy while also exploring the feasibility of predicting bleeding from Dieulafoy’s lesion prior to endoscopy in cases of obscure gastrointestinal bleeding. Methods: A comprehensive analysis of our database was conducted, identifying 38 patients who received a diagnosis of Dieulafoy’s lesion and subsequently underwent treatment via double-balloon endoscopy. The clinical background, diagnosis, and treatment details of patients with Dieulafoy’s lesion were carefully examined. Results: The median age of the 38 patients was 72 years, and 50% of the patients were male. A total of 26 (68%) patients exhibited a high comorbidity index. The upper jejunum and lower ileum were the most frequently reported locations for the occurrence of Dieulafoy’s lesion in the small bowel. The detected Dieulafoy’s lesions exhibited active bleeding (n = 33) and an exposed vessel with plaque on the surface (n = 5). Rebleeding after endoscopic treatment occurred in 8 patients (21%, median period: 7 days, range: 1-366 days). We conducted an analysis to determine the definitive nature of the initial double-balloon endoscopy diagnosis. Multivariate analysis revealed that hematochezia of ≥ 2 episodes constituted the independent factor associated with ≥ 2 double-balloon endoscopy diagnoses. Additionally, we explored factors associated with rebleeding following endoscopic treatment. Although the number of hemoclips utilized displayed a likely association, multivariate analysis did not identify any independent factor associated with rebleeding. Conclusion: If a patient encounters multiple instances of hematochezia, promptly scheduling balloon-assisted endoscopy, equipped with optional instruments without delay is advised, after standard endoscopic evaluation with esophagogastroduodenoscopy and colonoscopy is unrevealing.

    DOI: 10.1186/s12876-023-02913-1

    Web of Science

    Scopus

    PubMed

  10. Protocol for measuring transcytosis and recycling of IgG in intestinal epithelial Caco-2 cells and primary human intestinal organoids

    Maeda, K; Gwilt, KB; Schmieder, SS; Zachos, NC; Lencer, WI

    STAR PROTOCOLS   4 巻 ( 2 )   2023年6月

  11. Efficacy of 1-kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised, double-blind, placebo-controlled pilot study 査読有り 国際誌

    Ikegami, S; Nakamura, M; Honda, T; Yamamura, T; Maeda, K; Sawada, T; Ishikawa, E; Yamamoto, K; Furune, S; Ishikawa, T; Furukawa, K; Ohno, E; Ishigami, M; Kinoshita, F; Kadota, Y; Tochio, T; Shimomura, Y; Hirooka, Y; Kawashima, H

    ALIMENTARY PHARMACOLOGY & THERAPEUTICS   57 巻 ( 11 ) 頁: 1249 - 1257   2023年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Alimentary Pharmacology and Therapeutics  

    Background: Ulcerative colitis involves an excessive immune response to intestinal bacteria. Whether administering prebiotic 1-kestose is effective for active ulcerative colitis remains controversial. Aims: This randomised, double-blind, placebo-controlled pilot trial investigated the efficacy of 1-kestose against active ulcerative colitis. Methods: Forty patients with mild to moderate active ulcerative colitis were randomly treated with 1-kestose (N = 20) or placebo (maltose, N = 20) orally for 8 weeks in addition to the standard treatment. The Lichtiger clinical activity index and Ulcerative Colitis Endoscopic Index of Severity were determined. Faecal samples were analysed to evaluate the gut microbiome and metabolites. Results: The clinical activity index at week 8 was significantly lower in the 1-kestose group than in the placebo group (3.8 ± 2.7 vs. 5.6 ± 2.1, p = 0.026). Clinical remission and response rates were higher in the 1-kestose group than in the placebo group (remission: 55% vs. 20%, p = 0.048; response: 60% vs. 25%, p = 0.054). The Ulcerative Colitis Endoscopic Index of Severity at week 8 was not significantly different (2.8 ± 1.6 vs. 3.5 ± 1.6, p = 0.145). Faecal analysis showed significantly reduced alpha-diversity in the 1-kestose group, with a decreased relative abundance of several bacteria, including Ruminococcus gnavus group. The short-chain fatty acid levels were not significantly different between the groups. The incidence of adverse events was comparable between the groups. Discussion: Oral 1-kestose is well tolerated and provides clinical improvement for patients with mild to moderate ulcerative colitis through modulation of the gut microbiome.

    DOI: 10.1111/apt.17387

    Web of Science

    Scopus

    PubMed

  12. ENDOSCOPIC TREATMENT OF DUODENAL NEUROENDOCRINE TUMORS

    Furukawa, K; Furune, S; Ishikawa, E; Sawada, T; Maeda, K; Yamamura, T; Ishikawa, T; Nakamura, M; Kawashima, H

    GASTROINTESTINAL ENDOSCOPY   97 巻 ( 6 ) 頁: AB1211 - AB1212   2023年6月

     詳細を見る

  13. CO<sub>2</sub> enterography in endoscopic retrograde cholangiography using double-balloon endoscopy: A randomized clinical trial 査読有り 国際誌

    Murate, K; Nakamura, M; Yamamura, T; Maeda, K; Sawada, T; Ishikawa, E; Kida, Y; Esaki, M; Hamazaki, M; Iida, T; Mizutani, Y; Yamao, K; Ishikawa, T; Furukawa, K; Ohno, E; Honda, T; Ishigami, M; Kinoshita, F; Ando, M; Kawashima, H

    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   38 巻 ( 5 ) 頁: 761 - 767   2023年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Journal of Gastroenterology and Hepatology (Australia)  

    Background and Aim: Double-balloon endoscopic retrograde cholangiography (DBERC) is a valuable procedure for patients with altered gastrointestinal anatomy. Nonetheless, it is time-consuming and burdensome for both patients and endoscopists, partly because route selection in the reconstructed bowel with complicating loop is challenging. Carbon dioxide insufflation enterography is reportedly useful for route selection in the blind loop. This prospective randomized clinical trial investigated the usefulness of carbon dioxide insufflation enterography for route selection by comparing it with conventional observation. Methods: Patients scheduled to undergo DBERC were consecutively registered. They were divided into carbon dioxide insufflation enterography and conventional groups via randomization according to stratification factors, type of reconstruction methods, and experience with DBERC. The primary endpoint was the correct rate of initial route selection. The secondary endpoints were the insertion time, examination time, amount of anesthesia drugs, and complications. Results: The correct rate of route selection was significantly higher in the carbon dioxide insufflation enterography group (23/25, 92%) than in the visual method (15/25, 60%) (P = 0.018). The insertion time was significantly shorter in the carbon dioxide insufflation enterography group than in the visual group (10.8 ± 11.1 min vs 29.8 ± 15.7 min; P < 0.001). No significant differences in complications were noted between the two groups. The amounts of sedatives and analgesics used were significantly lower in the carbon dioxide insufflation enterography group (P < 0.001 and P < 0.001, respectively). Conclusions: Carbon dioxide insufflation enterography can reduce the burden of DBERC on patients and endoscopists by shortening the examination time and reducing the amount of medication.

    DOI: 10.1111/jgh.16112

    Web of Science

    Scopus

    PubMed

  14. Novel endoscopic approaches using the endocytoscopy for the target biopsy in esophageal eosinophilia

    Muroi, K; Kakushima, N; Furukawa, K; Furune, S; Ito, N; Hirose, T; Hida, E; Suzuki, T; Suzuki, T; Hirai, K; Shibata, H; Ishikawa, E; Sawada, T; Maeda, K; Yamamura, T; Ohno, E; Nakamura, M; Fujishiro, M; Kawashima, H

    ESOPHAGUS   20 巻 ( 2 ) 頁: 325 - 332   2023年4月

     詳細を見る

    記述言語:英語   出版者・発行元:Esophagus  

    Background and aims: Multiple biopsies are recommended for the diagnosis of eosinophilic esophagitis (EoE) because inflammatory changes are frequently patchy. Reports on EoE using endocytoscopy (ECS) are limited. This present study aimed to assess if diagnostic yield improves by adding ECS on conventional white light imaging (WLI) in patients with esophageal eosinophilia (EE). Methods: A total of 284 biopsy specimens from 71 patients with a known diagnosis of EE were enrolled and divided into the WLI group (156 specimens) or the ECS group (128 specimens). Four biopsies from 5 and 10 cm proximal to the esophagogastric junction were taken from each patient. In the ECS group, the biopsy was performed where bilobed nuclei were observed. The biopsy sensitivity for EE, eosinophil count of a single specimen and the biopsy sensitivity of each endoscopic finding were evaluated between both groups. Results: The sensitivity of a single biopsy specimen was higher in the ECS group than that of the WLI group (62.5 vs. 41.7%, P < 0.001). In addition, the median eosinophil count in the ECS group was significantly higher [19 vs. 6.5/high-power field (HPF), P < 0.001]. For each endoscopic finding, ECS-based biopsy had higher sensitivity than that of WLI in the diagnosis of edema (33.1 vs. 11.3%, P = 0.007) and linear furrows (75.8 vs. 52%, P = 0.005). Conclusion: This study showed that adding ECS to WLI improved the biopsy sensitivity and eosinophil detection in patients with EE.

    DOI: 10.1007/s10388-022-00963-0

    Web of Science

    Scopus

    PubMed

  15. Proteomic Analysis Reveals Changes in Tight Junctions in the Small Intestinal Epithelium of Mice Fed a High-Fat Diet 国際誌

    Muto, H; Honda, T; Tanaka, T; Yokoyama, S; Yamamoto, K; Ito, T; Imai, N; Ishizu, Y; Maeda, K; Ishikawa, T; Adachi, S; Sato, C; Tsuji, NM; Ishigami, M; Fujishiro, M; Kawashima, H

    NUTRIENTS   15 巻 ( 6 )   2023年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Nutrients  

    The impact of a high-fat diet (HFD) on intestinal permeability has been well established. When bacteria and their metabolites from the intestinal tract flow into the portal vein, inflammation in the liver is triggered. However, the exact mechanism behind the development of a leaky gut caused by an HFD is unclear. In this study, we investigated the mechanism underlying the leaky gut related to an HFD. C57BL/6J mice were fed an HFD or control diet for 24 weeks, and their small intestine epithelial cells (IECs) were analyzed using deep quantitative proteomics. A significant increase in fat accumulation in the liver and a trend toward increased intestinal permeability were observed in the HFD group compared to the control group. Proteomics analysis of the upper small intestine epithelial cells identified 3684 proteins, of which 1032 were differentially expressed proteins (DEPs). Functional analysis of DEPs showed significant enrichment of proteins related to endocytosis, protein transport, and tight junctions (TJ). Expression of Cldn7 was inversely correlated with intestinal barrier function and strongly correlated with that of Epcam. This study will make important foundational contributions by providing a comprehensive depiction of protein expression in IECs affected by HFD, including an indication that the Epcam/Cldn7 complex plays a role in leaky gut.

    DOI: 10.3390/nu15061473

    Web of Science

    Scopus

    PubMed

  16. Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn's Disease 査読有り 国際誌

    Kawamura, T; Yamamura, T; Nakamura, M; Maeda, K; Sawada, T; Ishikawa, E; Iida, T; Mizutani, Y; Ishikawa, T; Kakushima, N; Furukawa, K; Ohno, E; Honda, T; Kawashima, H; Ishigami, M

    INFLAMMATORY BOWEL DISEASES   29 巻 ( 2 ) 頁: 245 - 253   2023年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Inflammatory Bowel Diseases  

    Background: Mucosal healing, confirmed by endoscopic evaluation, is the long-term goal of treatment for Crohn’s disease (CD). Leucine-rich alpha-2 glycoprotein (LRG) is a new serum biomarker correlated with disease activity in inflammatory bowel disease. However, studies evaluating its relationship with CD, particularly in the context of small intestinal lesions, are scarce.The aim of this study was to investigate the accuracy of LRG in assessing endoscopic activity, especially remission, in patients with CD. Methods: Between July 2020 and March 2021, 72 patients with CD who underwent LRG testing and double-balloon endoscopy at the same time were included. Endoscopic activity was evaluated using the applied Simple Endoscopic Score for Crohn’s disease, including small intestine lesions.The relationship of LRG with clinical symptoms and endoscopic activity was assessed, and its predictive accuracy was evaluated. Results: Leucine-rich alpha-2 glycoprotein showed a significant positive correlation with endoscopic activity (r = 0.619, P < .001), even in patients with active lesions in the small intestine (r = 0.626, P < .001). Multivariate logistic regression revealed that LRG was the only factor associated with endoscopic remission. An LRG cutoff value of 8.9 μg/mL had a sensitivity of 93.3%; specificity of 83.3%; positive predictive value of 96.6%; negative predictive value of 71.4%; accuracy of 91.7%; and area under the curve of 0.904 for the prediction of endoscopic remission. Conclusions: Leucine-rich alpha-2 glycoprotein can be used in assessing endoscopic activity and is a reliable marker of endoscopic remission in CD patients. It can be an intermediate target in the treatment of CD.

    DOI: 10.1093/ibd/izac076

    Web of Science

    Scopus

    PubMed

  17. SMALL INTESTINAL GANGLIONEUROMATOSIS IN A PATIENT WITH NEUROFIBROMATOSIS TYPE 1: A CASE REPORT

    Kida Y., Sawada T., Ishikawa E., Sakakibara A., Yamamura T., Maeda K., Esaki M., Hamazaki M., Murate K., Nakamura M.

    Gastroenterological Endoscopy   65 巻 ( 7 ) 頁: 1232 - 1238   2023年

     詳細を見る

    記述言語:日本語   出版者・発行元:Gastroenterological Endoscopy  

    A 50-year-old woman with neurofibromatosis type 1 who hospitalized for chronic diarrhea was transferred to our hospital for evaluation of small intestinal dilatation and thickening. Transoral double-balloon enteroscopy revealed jejunal dilatation and suppressed peristalsis; however, mucosal inflammation, such as ulcers or erosions were not detected. Transanal double-balloon enteroscopy detected the intestinal stenosis with inflammatory polyps and a longitudinal ulcer. Histopathological evaluation of duodenal, jejunal, and ileal specimens by biopsy revealed ganglion cells and Schwannian cells; therefore, the patient was diagnosed with ganglioneuromatosis with neurofibromatosis type 1. Small intestinal dilatation was associated with suppressed peristalsis caused by ganglioneuromatosis and was diagnosed as secondary chronic intestinal pseudo-obstruction. Abdominal distention persisted despite conservative therapy. However, she remained asymptomatic, and oral intake remained unaffected. Ganglioneuromatosis is rare; however, clinicians should be mindful that ganglioneuromatosis is an abdominal complication associated with systemic disease such as neurofibromatosis type 1 and multiple endocrine neoplasia type 2B.

    DOI: 10.11280/gee.65.1232

    Scopus

    CiNii Research

  18. Diagnostic Performance of Endocytoscopy for Esophageal Eosinophilia. 査読有り 国際誌

    Hida E, Muroi K, Kakushima N, Furune S, Ishikawa E, Mizutani Y, Sawada T, Keiko M, Yamamura T, Ishikawa T, Furukawa K, Ohno E, Nakamura M, Nishida K, Fujishiro M, Kawashima H

    Digestion   104 巻 ( 3 ) 頁: 202 - 211   2023年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1159/000528174

    PubMed

  19. Factors Related to Delayed Adverse Events of Endoscopic Submucosal Dissection in the Duodenum. 査読有り 国際誌

    Kawamura T, Hirose T, Kakushima N, Furukawa K, Furune S, Ishikawa E, Sawada T, Keiko M, Yamamura T, Ishikawa T, Ohno E, Nakamura M, Honda T, Ishigami M, Kawashima H, Fujishiro M

    Digestive diseases (Basel, Switzerland)   41 巻 ( 1 ) 頁: 80 - 88   2023年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1159/000522362

    PubMed

  20. 特集 消化管内視鏡治療のリスク克服に向けて 1.待機的内視鏡治療に潜むリスクとそのマネジメント(6)大腸EMR/ESD

    山村 健史, 中村 正直, 前田 啓子, 澤田 つな騎, 石川 恵里, 古川 和宏, 川嶋 啓揮

    臨床消化器内科   38 巻 ( 1 ) 頁: 42 - 47   2022年12月

     詳細を見る

    出版者・発行元:日本メディカルセンター  

    DOI: 10.19020/cg.0000002478

    CiNii Research

  21. Network Analysis of Gut Microbiota Including <i>Fusobacterium</i> and Oral Origin Bacteria and Their Distribution on Tumor Surface, Normal Mucosa, and in Feces in Patients with Colorectal Cancer

    Ohashi, A; Yamamura, T; Nakamura, M; Maeda, K; Sawada, T; Ishikawa, E; Yamamoto, K; Ishikawa, T; Kakushima, N; Furukawa, K; Ohno, E; Honda, T; Kawashima, H; Ishigami, M; Fujishiro, M

    DIGESTION   103 巻 ( 6 ) 頁: 451 - 461   2022年12月

     詳細を見る

    記述言語:英語   出版者・発行元:Digestion  

    Introduction: Fusobacterium and several bacteria are reported to be associated with colorectal cancer (CRC). However, their relationship and whether they cause CRC or are just adapted to the cancerous environment is not known. We approached this subject by investigating the correlation and distribution of the bacteria throughout the colon in patients with CRC and elucidated the relationship between microbiota and CRC. Methods: Twenty-five patients with CRC who underwent colonoscopy for endoscopic submucosal dissection or surgery were prospectively enrolled. Fecal samples were taken before bowel preparation, and mucosal samples were collected from three sites (tumor surface, tumor-adjacent mucosa, and cecum) during colonoscopy using a cytology brush. The microbiota was identified and analyzed by sequencing of the 16S rRNA gene of the V3-V4 region. We evaluated the correlation between the bacteria based on network analysis and the distribution of Fusobacterium in the colon. Results: A network consisting of many bacteria was found in all sites; especially, oral origin bacteria including Fusobacterium formed a positively correlated network on tumor surface. Streptococcus showed a significantly higher relative abundance on tumor surface than in feces. The relative abundance of Fusobacterium had significant positive correlations between tumor surface and feces, tumor-adjacent mucosa, and cecum. Conclusion: In patients with CRC, many bacteria were correlated with each other, and Fusobacterium and oral origin bacteria formed a positively correlated network on tumor surface. Fusobacterium was equally distributed on tumor surface and throughout the lumen and mucus in the colon. In the colon where Fusobacterium is widely distributed, Fusobacterium would adhere to the tumor surface and be correlated with oral origin bacteria to make a microenvironment that is favorable for CRC.

    DOI: 10.1159/000527170

    Web of Science

    Scopus

    PubMed

  22. The effects of ustekinumab on small intestinal lesions and stenotic lesions

    Wada Hirotaka, Murate Kentaro, Nakamura Masanao, Furukawa Kazuhiro, Kakushima Naomi, Yamamura Takeshi, Maeda Keiko, Sawada Tsunaki, Ishikawa Eri, Ishikawa Takuya, Ohno Eizaburo, Honda Takashi, Kawashima Hiroki, Nakayama Goro, Hattori Norifumi, Umeda Shinichi, Ishigami Masatoshi

    NAGOYA JOURNAL OF MEDICAL SCIENCE   84 巻 ( 4 ) 頁: 825 - 838   2022年11月

     詳細を見る

    記述言語:英語   出版者・発行元:Nagoya Journal of Medical Science  

    Crohn’s disease patients suffer from symptoms originating from small bowel lesions, including strictures. As many of these patients also have a potential risk of surgery, it is important to consider various therapeutic strategies for small bowel lesions. We retrospectively analyzed the therapeutic effects of ustekinumab, interleukin-12 and -23 blocker, for small intestinal lesions and intestinal stenosis in order to contribute to the optimal management of Crohn’s disease. Patients who underwent total colonoscopy or small bowel endoscopy before and after the introduction of ustekinumab were enrolled in this study. The colonoscopy findings were evaluated by the simple endoscopic score for Crohn’s disease, and small bowel endoscopy findings were evaluated using the modified simple endoscopic score for Crohn’s disease. Endoscopic scores were compared before and after the introduction of ustekinumab and between the responders and non-responders to ustekinumab. Responders were defined as those whose Crohn’s disease activity index score at 24 weeks fell below 150 points, or those whose score decreased by more than 100 points from the pre-induction level. A total of 50 patients were enrolled in the study, and the number of responders was 35. Pre-induction simple endoscopic scores were lower for responders, but no significant difference was observed in the modified simple endoscopic scores. The total decrease in the endoscopic score was significantly higher in the responders for both the small and large intestine. Use of ustekinumab as a first-line treatment for patients with small bowel lesions or stricture-prone lesions may be a new treatment consideration in the future.

    DOI: 10.18999/nagjms.84.4.825

    Web of Science

    Scopus

    PubMed

  23. Analysis of immunologic comorbidities in ulcerative colitis patients: a tool to prevent exacerbations in ulcerative colitis cases 査読有り

    Meza, MRR; Nakamura, M; Yamamura, T; Maeda, K; Sawada, T; Ishikawa, E; Kakushima, N; Furukawa, K; Iida, T; Mizutani, Y; Ishikawa, T; Ohno, E; Honda, T; Kawashima, H; Ishigami, M

    NAGOYA JOURNAL OF MEDICAL SCIENCE   84 巻 ( 4 ) 頁: 733 - 745   2022年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Nagoya Journal of Medical Science  

    There have been previous studies, especially in Western countries and even in some areas in Asia, about extra-intestinal manifestations (EIMs) and its link with the outcome of inflammatory bowel disease (IBD), which includes Crohn’s disease (CD), and ulcerative colitis (UC). This link is crucial when discussing a patient’s prognosis and important when dealing with UC management. The aim of this study was to clarify the most common comorbidities associated with UC, emphasizing immunologic comorbidities in Japan. This study was a retrospective analysis performed at Nagoya University Hospital. The data collection started in March, 2019, and continued for two years. We retrieved the medical records of 105 patients with UC diagnosis, from which the data of 176 EIMs were extracted and analyzed. Results showed that EIMs with UC in the active phase accounted for 43.7% of total EIMs. Twenty-six patients with immune-mediated inflammatory disease frequently had an active phase (odds ratio [OR] 3.84, 99% CI, 1.44–10.27). Comorbidities showing an active manifestation of symptoms and UC in the active phase were significantly correlated in patients with immunological comorbidities, such as peripheral arthritis (r = 0.97, p < 0.01) and rheumatoid arthritis (RA) (r = 0.99, p < 0.01), as well as in patients with primary sclerosis cholangitis (PSC) (r = 0.98, p < 0.01). In conclusion, this analysis suggests the importance of having full comprehension of how immunological comorbidities affect the natural development of UC, which is of vital importance to prevent further UC complications and properly adjust the management of the disease.

    DOI: 10.18999/nagjms.84.4.733

    Web of Science

    Scopus

    PubMed

  24. Fecal microbiota transplantation in the treatment of irritable bowel syndrome: a single-center prospective study in Japan 査読有り 国際誌

    Hamazaki, M; Sawada, T; Yamamura, T; Maeda, K; Mizutani, Y; Ishikawa, E; Furune, S; Yamamoto, K; Ishikawa, T; Kakushima, N; Furukawa, K; Ohno, E; Honda, T; Kawashima, H; Ishigami, M; Nakamura, M; Fujishiro, M

    BMC GASTROENTEROLOGY   22 巻 ( 1 ) 頁: 342 - 342   2022年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BMC Gastroenterology  

    Background: Fecal microbiota transplantation (FMT) is a potential treatment for irritable bowel syndrome (IBS), but its efficacy in Japanese IBS patients is unknown. This study aimed to evaluate the efficacy, side effects, and microbiome changes following FMT in Japanese IBS patients. Methods: Seventeen Japanese patients with refractory IBS received FMT (4 donors) under colonoscopy. Responders were defined by an improvement in the IBS severity index (IBS-SI) of 50 points or more after 12 weeks. We evaluated the IBS-SI and Bristol Stool Form Scale (BSFS) and compared the diversity and microbiome before and 12 weeks after FMT. For the microbiome, we analyzed the V3–V4 region of the 16S rRNA gene. Results: IBS-SI decreased an average of 115.58 points after 12 weeks, and 10 patients (58.8%) were considered responders. Eight patients with diarrhea (66.7%) and three patients with constipation (60.0%) showed improvement in the BSFS. Two patients complained of mild abdominal pain, but there were no cases with severe side-effects. α-diversity was increased only in the responder group (p = 0.017). Patients who closely paralleled the donor microbiome had a higher rate of IBS-SI improvement. The relative abundance of Neisseria and Akkermansia increased and Desulfovibrio and Delftia were decreased in the responder group after FMT. Conclusions: Following FMT, about 60% of Japanese patients with IBS showed improvement in both the IBS-SI and BSFS, without severe side effects. Increased α-diversity and similarity to the donor microbiome after FMT may be associated with better treatment effects. Trial registration: This study was registered in the University Hospital Medical Information Network Clinical Trial Registration (UMIN000026363). Registered 31 May 2017, https://rctportal.niph.go.jp/s/detail/um?trial_id=UMIN000026363. The study was registered prospectively.

    DOI: 10.1186/s12876-022-02408-5

    Web of Science

    Scopus

    PubMed

  25. Effects of steroid use for stenosis prevention after endoscopic submucosal dissection for cervical esophageal cancer 査読有り

    Muroi, K; Kakushima, N; Furukawa, K; Furune, S; Ito, N; Hirose, T; Ishikawa, E; Mizutani, Y; Sawada, T; Maeda, K; Yamamura, T; Ishikawa, T; Ohno, E; Nakamura, M; Kawashima, H; Funasaka, K; Miyahara, R; Fujishiro, M

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   27 巻 ( 5 ) 頁: 940 - 947   2022年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:International Journal of Clinical Oncology  

    Background and aim: Esophageal stenosis is a serious complication after endoscopic submucosal dissection (ESD) for thoracic esophageal cancer (TEC), and steroid has been applied for stenosis prevention. However, the rate of stenosis and effect of steroid for ESD of cervical esophageal cancer (CEC) remain unknown. The aim was to clarify the rate and managements of post-ESD stenosis for CEC. Methods: A total of 325 lesions with 272 patients who underwent ESD for esophageal cancers were enrolled and were divided to the CEC group (43 lesions) or the TEC group (282 lesions). Patient characteristics, clinicopathological features, procedure-related outcomes of esophageal ESD, stenosis rate and clinical outcome of steroid use cases were evaluated. Results: More patients in the CEC group received preventive steroid treatment compared to the TEC group (37.2% vs 14.5%, P = 0.001). The rate of post-ESD stenosis tended to be higher in the CEC group (11.6%) than in the TEC group (6.7%). For cases of 3/4 ≤ of circumference, local injection with oral steroid had lower stenosis rate than local injection only in both groups (CEC 40% vs 100%, TEC 30.7% vs 56.3%). More sessions and longer duration of dilation were needed to release the stenosis in the CEC group (20 times vs. 5 times, P = 0.015; 196 days vs. 55 days, P = 0.043). Conclusion: The post-ESD stenosis rate of CEC tended to be higher than that of TEC. More intensive preventive measures for post-ESD stenosis may be needed for CEC than TEC.

    DOI: 10.1007/s10147-022-02139-3

    Web of Science

    Scopus

    PubMed

  26. Gelsolin as a Potential Biomarker for Endoscopic Activity and Mucosal Healing in Ulcerative Colitis 査読有り 国際誌

    Maeda, K; Nakamura, M; Yamamura, T; Sawada, T; Ishikawa, E; Oishi, A; Ikegami, S; Kakushima, N; Furukawa, K; Iida, T; Mizutani, Y; Ishikawa, T; Ohno, E; Honda, T; Ishigami, M; Kawashima, H

    BIOMEDICINES   10 巻 ( 4 )   2022年4月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Biomedicines  

    The therapeutic goal in ulcerative colitis is mucosal healing, which requires improved non-invasive biomarkers to evaluate disease activity. Gelsolin is associated with several autoimmune diseases, and here, we aimed to analyze its usefulness as a serological biomarker for clinical and endoscopic activities in ulcerative colitis. Patients with ulcerative colitis (n = 138) who had undergone blood tests and colonoscopy were included. Serum gelsolin was measured using enzyme-linked immunosorbent assay, and correlation between the gelsolin level and clinical and endoscopic activities was examined. The serum gelsolin level in patients with ulcerative colitis was significantly lower than that in healthy subjects, and it decreased in proportion to increasing Mayo score and Mayo endoscopic subscore. The area under the curve for correlation between clinical and endoscopic remission and serum gelsolin level was higher than that for C-reactive protein. Furthermore, in C-reactive protein-negative patients, the serum gelsolin level was lower in the active phase than in remission. Our findings indicate that the serum gelsolin level correlates with clinical and endoscopic activities in ulcerative colitis, has a higher sensitivity and specificity than C-reactive protein, and can detect mucosal healing, suggesting that gelsolin can be used as a biomarker for ulcerative colitis.

    DOI: 10.3390/biomedicines10040872

    Web of Science

    Scopus

    PubMed

  27. Diagnostic performance of endoscopic classifications for neoplastic lesions in patients with ulcerative colitis: A retrospective case-control study 査読有り 国際誌

    Kida, Y; Yamamura, T; Maeda, K; Sawada, T; Ishikawa, E; Mizutani, Y; Kakushima, N; Furukawa, K; Ishikawa, T; Ohno, E; Kawashima, H; Nakamura, M; Ishigami, M; Fujishiro, M

    WORLD JOURNAL OF GASTROENTEROLOGY   28 巻 ( 10 ) 頁: 1055 - 1066   2022年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:World Journal of Gastroenterology  

    BACKGROUND It is unclear whether the Japan Narrow-Band Imaging Expert Team (JNET) classification and pit pattern classification are applicable for diagnosing neoplastic lesions in patients with ulcerative colitis (UC). AIM To clarify the diagnostic performance of these classifications for neoplastic lesions in patients with UC. METHODS This study was conducted as a single-center, retrospective case-control study. Twenty-one lesions in 19 patients with UC-associated neoplasms (UCAN) and 23 lesions in 22 UC patients with sporadic neoplasms (SN), evaluated by magnifying image-enhanced endoscopy, were retrospectively and separately assessed by six endoscopists (three experts, three non-experts), using the JNET and pit pattern classifications. The results were compared with the pathological diagnoses to evaluate the diagnostic performance. Inter- and intra-observer agreements were calculated. RESULTS In this study, JNET type 2A and pit pattern type III/IV were used as indicators of low-grade dysplasia, JNET type 2B and pit pattern type VI low irregularity were used as indicators of highgrade dysplasia to shallow submucosal invasive carcinoma, JNET type 3 and pit pattern type VI high irregularity/VN were used as indicators of deep submucosal invasive carcinoma. In the UCAN group, JNET type 2A and pit pattern type III/IV had a low positive predictive value (PPV; 50.0% and 40.0%, respectively); however, they had a high negative predictive value (NPV; 94.7% and 100%, respectively). Conversely, in the SN group, JNET type 2A and pit pattern type III/IV had a high PPV (100% for both) but a low NPV (63.6% and 77.8%, respectively). In both groups, JNET type 3 and pit pattern type VI-high irregularity/VN showed high specificity. The interobserver agreement of JNET classification and pit pattern classification for UCAN among experts were 0.401 and 0.364, in the same manner for SN, 0.666 and 0.597, respectively. The intra-observer agreements of JNET classification and pit pattern classification for UCAN among experts were 0.387, 0.454, for SN, 0.803 and 0.567, respectively. CONCLUSION The accuracy of endoscopic diagnosis using both classifications was lower for UCAN than for SN. Endoscopic diagnosis of UCAN tended to be underestimated compared with the pathological results.

    DOI: 10.3748/wjg.v28.i10.1055

    Web of Science

    Scopus

    PubMed

  28. Artificial intelligence-based diagnosis of upper gastrointestinal subepithelial lesions on endoscopic ultrasonography images 査読有り

    Hirai, K; Kuwahara, T; Furukawa, K; Kakushima, N; Furune, S; Yamamoto, H; Marukawa, T; Asai, H; Matsui, K; Sasaki, Y; Sakai, D; Yamada, K; Nishikawa, T; Hayashi, D; Obayashi, T; Komiyama, T; Ishikawa, E; Sawada, T; Maeda, K; Yamamura, T; Ishikawa, T; Ohno, E; Nakamura, M; Kawashima, H; Ishigami, M; Fujishiro, M

    GASTRIC CANCER   25 巻 ( 2 ) 頁: 382 - 391   2022年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Gastric Cancer  

    Background: Endoscopic ultrasonography (EUS) is useful for the differential diagnosis of subepithelial lesions (SELs); however, not all of them are easy to distinguish. Gastrointestinal stromal tumors (GISTs) are the commonest SELs, are considered potentially malignant, and differentiating them from benign SELs is important. Artificial intelligence (AI) using deep learning has developed remarkably in the medical field. This study aimed to investigate the efficacy of an AI system for classifying SELs on EUS images. Methods: EUS images of pathologically confirmed upper gastrointestinal SELs (GIST, leiomyoma, schwannoma, neuroendocrine tumor [NET], and ectopic pancreas) were collected from 12 hospitals. These images were divided into development and test datasets in the ratio of 4:1 using random sampling; the development dataset was divided into training and validation datasets. The same test dataset was diagnosed by two experts and two non-experts. Results: A total of 16,110 images were collected from 631 cases for the development and test datasets. The accuracy of the AI system for the five-category classification (GIST, leiomyoma, schwannoma, NET, and ectopic pancreas) was 86.1%, which was significantly higher than that of all endoscopists. The sensitivity, specificity, and accuracy of the AI system for differentiating GISTs from non-GISTs were 98.8%, 67.6%, and 89.3%, respectively. Its sensitivity and accuracy were significantly higher than those of all the endoscopists. Conclusion: The AI system, classifying SELs, showed higher diagnostic performance than that of the experts and may assist in improving the diagnosis of SELs in clinical practice.

    DOI: 10.1007/s10120-021-01261-x

    Web of Science

    Scopus

    PubMed

  29. Fecal incontinence and oral regurgitation during duodenal endoscopic submucosal dissection using the water pressure method 査読有り 国際誌

    Takada, Y; Hirose, T; Nishida, K; Kakushima, N; Furukawa, K; Furune, S; Ishikawa, E; Sawada, T; Maeda, K; Yamamura, T; Ishikawa, T; Ohno, E; Nakamura, M; Honda, T; Ishigami, M; Kawashima, H; Fujishiro, M

    DIGESTIVE ENDOSCOPY   34 巻 ( 3 ) 頁: 526 - 534   2022年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Digestive Endoscopy  

    Objectives: Endoscopic submucosal dissection (ESD) in the duodenum is challenging. The water pressure method (WP-ESD) has been developed with a decreased rate of perforation. However, details of perioperative adverse events of WP-ESD are unknown. The purpose of this study was to clarify the frequency and related factors of fecal incontinence and oral regurgitation during WP-ESD. Methods: A chart-based retrospective analysis was performed on 43 patients who underwent duodenal WP-ESD. The saline volume given into the body was calculated in all cases. All adverse events during WP-ESD until 6 weeks were extracted, and factors related to intraoperative fecal incontinence or oral regurgitation were analyzed. The frequency of fecal incontinence and oral regurgitation was also compared to those of 83 conventional ESD cases. Results: In WP-ESD, intraoperative fecal incontinence occurred in 12 (28%), oral regurgitation in six (14%), and aspiration pneumonia in one patient. For fecal incontinence, the infusion speed (saline volume divided by resection time) around 17 mL/min was a significant factor in multivariable analysis. For oral regurgitation, only tumor size was a significant factor in univariate analysis (P = 0.027). Significant difference was observed in the frequency of fecal incontinence between WP-ESD and conventional ESD (28% vs. 0%, P < 0.001), but no difference was observed in oral regurgitation or aspiration pneumonia. Conclusions: Intraoperative fecal incontinence is a unique adverse event of WP-ESD related to the infusion speed. WP-ESD did not pose a risk for oral regurgitation, but we should be aware of the risk in large tumor cases.

    DOI: 10.1111/den.14070

    Web of Science

    Scopus

    PubMed

  30. 今月の主題 炎症性腸疾患の粘膜治癒を再考する 主題 Crohn病における小腸粘膜治癒評価の意義-小腸カプセル内視鏡の立場から

    中村 正直, 山村 健史, 前田 啓子, 澤田 つな騎, 石川 恵里, 角嶋 直美, 古川 和宏, 飯田 忠, 水谷 泰之, 石川 卓哉, 大野 栄三郎, 川嶋 啓揮, 藤城 光弘

    胃と腸   57 巻 ( 2 ) 頁: 183 - 189   2022年2月

     詳細を見る

    出版者・発行元:株式会社医学書院  

    DOI: 10.11477/mf.1403202660

    CiNii Research

  31. Depletion of the apical endosome in response to viruses and bacterial toxins provides cell-autonomous host defense at mucosal surfaces 査読有り 国際誌

    Maeda, K; Zachos, NC; Orzalli, MH; Schmieder, SS; Chang, D; Gwilt, KB; Doucet, M; Baetz, NW; Lee, S; Crawford, SE; Estes, MK; Kagan, JC; Turner, JR; Lencer, WI

    CELL HOST & MICROBE   30 巻 ( 2 ) 頁: 216 - +   2022年2月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.chom.2021.12.011

    Web of Science

    PubMed

  32. Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis 査読有り

    Nakamura, M; Yamamura, T; Maeda, K; Sawada, T; Mizutani, Y; Ishikawa, E; Ishikawa, T; Kakushima, N; Furukawa, K; Ohno, E; Kawashima, H; Honda, T; Ishigami, M; Fujishiro, M

    NAGOYA JOURNAL OF MEDICAL SCIENCE   84 巻 ( 1 ) 頁: 169 - 179   2022年2月

     詳細を見る

    記述言語:英語   出版者・発行元:Nagoya Journal of Medical Science  

    Ulcerative colitis (UC) is an incurable, chronic inflammatory disease of the large bowel whose etiology and pathogenesis have not yet been comprehensively explained. Tofacitinib is a small molecule Janus kinase inhibitor that was introduced for treating refractory UC. We aimed to examine the efficacy and safety of tofacitinib for the treatment of 18 patients with UC. Continuous treatment rates were 50, 38, and 33% at 8, 24, and 52 weeks, respectively. Overall, 83.3% of these patients showed tumor necrosis factor (TNF) antibody failure status. When the effective status was defined as a Lichtiger index (LI) that decreased by 3 points or more or was less than 4 points and remission status was defined as an LI less than 4 points, the effective and remission rates (%) at 2, 8, and 16 weeks were 55.5 (10/18) and 22.2 (4/18), 38.8 (7/18) and 33.3 (6/18), and 38.8 (7/18) and 38.8 (7/18), respectively. Background characteristics of 2-week responders and non-responders were compared. C-reactive protein level in responders was significantly lower than that in non-responders, and the hemoglobin level in responders was significantly higher than that in non-responders. This study provides preliminary results of the effectiveness of tofacitinib even for TNF antibody and tacrolimus failure patients.

    DOI: 10.18999/nagjms.84.1.169

    Web of Science

    Scopus

    PubMed

  33. Evaluation of ulcerative colitis activity using transabdominal ultrasound shear wave elastography 査読有り 国際誌

    Yamada, K; Ishikawa, T; Kawashima, H; Ohno, E; Iida, T; Ishikawa, E; Mizutani, Y; Sawada, T; Maeda, K; Yamamura, T; Kakushima, N; Furukawa, K; Nakamura, M; Ishigami, M; Fujishiro, M

    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY   12 巻 ( 1 ) 頁: 618 - 626   2022年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Quantitative Imaging in Medicine and Surgery  

    Background: Transabdominal ultrasound (US) has been reported to be effective in the evaluation of ulcerative colitis (UC). US can measure shear wave elastography (SWE) and shear wave dispersion (SWD), which may be correlated with inflammation and necrosis. We aimed to investigate the relationship between UC activity and SWE and SWD. Methods: Patients with UC who underwent US within 2 days before or after a colonoscopy between April 2019 and March 2020 were included. SWE and SWD were measured in the sigmoid colon; the correlations of SWE and SWD with the Lichtiger index and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) were investigated. We also compared SWE and SWD between patients with mucosal healing and those in the active phase according to the UCEIS. Results: Twenty-six UC patients were enrolled. The median Lichtiger index, UCEIS, SWE values, and SWD values were 8 [interquartile range (IQR), 5.3–10.8], 4 (IQR, 3.3–5), 1.69 (IQR, 1.49–2.16) m/s, and 11.9 (IQR, 10.9–13.3) (m/s)/kHz, respectively. The Lichtiger index and UCEIS were negatively correlated with the SWE values (rs=−0.404 and rs=−0.506) but not with the SWD values (rs=0.004 and rs=0.002). The SWE values differed significantly between the mucosal healing and active phase groups [2.40 (IQR, 2.18–3.38) vs. 1.62 (IQR, 1.44–1.95) m/s, P=0.007], whereas the SWD values did not [13.1 (IQR, 7.05–21.6) vs. 11.9 (IQR, 11.1–13.2) (m/s)/kHz, P=0.918]. Conclusions: SWE may be useful for the evaluation of UC activity and could be a noninvasive method of assessing disease severity.

    DOI: 10.21037/qims-21-403

    Web of Science

    Scopus

    PubMed

  34. Preliminary Comparison of Endoscopic Brush and Net Catheters as the Sampling Tool to Analyze the Intestinal Mucus in the Rectum with Ulcerative Colitis Patients 国際誌

    Nakamura Masanao, Maeda Keiko, Yamamoto Kenta, Yamamura Takeshi, Sawada Tsunaki, Ishikawa Eri, Kakushima Naomi, Furukawa Kazuhiro, Iida Tadashi, Mizutani Yasuyuki, Ishikawa Takuya, Ohno Eizaburo, Honda Takashi, Ishigami Masatoshi, Kawashima Hiroki

    DIGESTION   103 巻 ( 3 ) 頁: 232 - 243   2022年

     詳細を見る

    記述言語:英語   出版者・発行元:Digestion  

    Background: The pathophysiology of ulcerative colitis (UC) remains unclear, but early lesions on the colorectal mucosal surface may play an important role in its etiology. Intestinal mucus samples, including inner and outer layers, are collected by net or brush catheters, but the quality of the samples obtained by each method has not been fully investigated. Objective: The purpose of this study was to compare the microbiome and protein content of intestinal mucus collected by net and brush catheters during colonoscopy. Methods: Intestinal mucus samples from the lower rectum of 4 patients with UC were collected using a net catheter, a brush catheter, and intestinal fluid suction. Microbiome and protein content were analyzed using 16S rRNA gene sequencing and mass spectrometry. Results: The patients demonstrated significant differences in microbiome alpha diversity (p < 0.05), but this difference was not observed between the sampling methods. Net catheter samples demonstrated higher total protein concentrations than brush catheter samples. The brush catheter group had more Lachnospira, a butyrate-producing bacterium, when compared to the net group. The brush catheter group also had more oral bacteria of Staphylococcus and Dialister in those with active phase when compared to the net group. Conclusions: Brush catheters are more likely to collect the intestinal mucus inner layer, whereas net catheters are more likely to collect larger samples that include the outer mucus layer, as well as the intestinal fluid. Two sampling methods with different types of collection of the mucosa may lead to different results among patients with mucosal vulnerabilities.

    DOI: 10.1159/000521929

    Web of Science

    Scopus

    PubMed

  35. 小腸Dieulafoy病変(矢野-山本分類Type 2a)の診断と治療についての臨床的検討

    中村 正直, 山村 健史, 前田 啓子, 澤田 つな騎, 石川 恵里, 川嶋 啓揮

    日本小腸学会学術集会プログラム・抄録集   6 巻 ( 0 ) 頁: 65 - 65   2022年

     詳細を見る

    記述言語:日本語   出版者・発行元:日本小腸学会  

    <p>【背景】小腸Dieulafoy病変は、内視鏡観察時に自然止血されている可能性があるため確定診断と治療が遅れる傾向を有する。一方では、Dieulafoy病変の臨床的特徴を把握しておくことによって診断のタイミングや治療戦略を事前に検討できるかもしれない。本研究の目的は、当院で経験された同病変の臨床的特徴を後方視的に調査し、その最適な診断と治療につき検討することであった。</p><p>【対象・方法】対象は当院において2003年6月から2022年7月の間に小腸出血が疑われダブルバルーン内視鏡(以下DBE)を施行し、Dieulafoy病変と診断、内視鏡治療を受けた36例であった。本研究におけるDieulafoy病変の定義は、粘膜面の変化は露出血管部のみとし、付着する血栓を認める場合と露出血管からの噴出性かそれに準じる活動性出血を認める場合とした。臨床的背景、治療方法などを検討した。</p><p>【結果】男性/女性は19/17例、平均年齢は71±10歳であった。33例でなんらかの基礎疾患を有していた。抗血栓薬の使用を19例で認め、ワーファリン10例、バイアスピリン7例(重複あり)の順で多かった。累計の出血エピソードは中央値で2回(1-18回)であった。最低血中ヘモグロビン値は5.9±1.7g/dl、赤血球輸血は2例以外の全例で行われていた。症状発現からDBEまでは中央値18日(2-63日)であった。DBE時の所見について、病変部位は深部十二指腸、上部空腸、中部空腸、下部空腸、中部回腸、下部回腸で各々3、18、8、2、2,6例で認められた(重複あり)。治療はクリッピング34例、APC凝固2例であった。偶発症は再出血10例(27.7%)、急性膵炎1例であった。</p><p>【結語】小腸Dieulafoy病変は診断に苦慮し、治療までに時間と輸血処置などを多く要していた。本病変が疑われた際には早めの内視鏡検査が検討される。</p>

    DOI: 10.32264/shocho.6.0_65

    CiNii Research

  36. Immunoproliferative Small Intestinal Disease Diagnosed by Double-balloon Endoscopy with Biopsy Sampling 査読有り

    Meza, MRR; Nakamura, M; Yamamura, T; Maeda, K; Sawada, T; Ishikawa, E; Kakushima, N; Furukawa, K; Ohno, E; Honda, T; Kawashima, H; Ishigami, M

    INTERNAL MEDICINE   61 巻 ( 17 ) 頁: 2593 - 2599   2022年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Internal Medicine  

    We herein report an 80-year-old man diagnosed with immunoproliferative small intestine disease (IPSID) via small bowel endoscopy with a biopsy. He developed persistent diarrhea and subsequently presented with hypoproteinemia and moderate anemia. Transanal double-balloon endoscopy showed prominent villous edema in the middle and lower ileum, while a histological examination showed high lymphocyte/plasma cell infiltration in the mucosal layer. Furthermore, an immunostaining analysis showed that Cluster of differentiation (CD)3 and CD20 were partially positive, while CD138 was diffusely positive. Immunoglobulin A positivity was also observed. He was diagnosed with IPSID and received a nutritional agent and minocycline. After three months, the patients’ symptoms improved.

    DOI: 10.2169/internalmedicine.8847-21

    Web of Science

    Scopus

    PubMed

    CiNii Research

  37. Real-world local recurrence rate after cold polypectomy in colorectal polyps less than 10 mm using propensity score matching 国際誌

    Saito Masashi, Yamamura Takeshi, Nakamura Masanao, Maeda Keiko, Sawada Tsunaki, Ishikawa Eri, Mizutani Yasuyuki, Ishikawa Takuya, Kakushima Naomi, Furukawa Kazuhiro, Ohno Eizaburo, Kawashima Hiroki, Ishigami Masatoshi, Fujishiro Mitsuhiro

    WORLD JOURNAL OF GASTROENTEROLOGY   27 巻 ( 47 ) 頁: 8182 - 8193   2021年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:World Journal of Gastroenterology  

    BACKGROUND Cold polypectomy (CP) is a simple and safe procedure for polyps less than 10 mm in size; however, there is concern about local recurrence following CP because of unidentified margins of excised specimens and the lack of tumor suppression effect by coagulation. Some clinical trials have evaluated local persistent recurrence; their results suggest that a higher rate of local recurrence has not been documented so far. There were few reports that observed the course over long periods of time after CP in clinical practice. AIM To evaluate the presence of local recurrence following CP and hot polypectomy (HP) using propensity score matching. METHODS We analyzed 275 patients who underwent polypectomy for non-pedunculated colorectal polyps less than 10 mm (959 Lesions) between October 2016 and 2017 and underwent follow-up endoscopy subsequently. We divided them into the CP group (706 Lesions), wherein CP was performed, and the HP group (253 Lesions), wherein HP was performed. Using propensity score matching, we extracted 215 Lesions in each group and evaluated the local recurrence and content of CP in the real clinic and adverse events using medical records. RESULTS After propensity score matching, there were no significant differences in the patients’ and their endoscopic background (age, use of antithrombotics, indications, size, morphology, location of polyps, and polypectomy device) between the groups. The mean duration between colorectal polypectomy and the next follow-up colonoscopy was 17.5 ± 7.1 (range, 6-39) mo in the CP group and 15.7 ± 6.0 (range, 6-35) mo in the HP group, which was significantly longer in the CP group (P = 0.005). The local recurrence rate was 0.93% in the CP group and 0.93% in the HP group, without a significant difference (P = 0.688). Additionally, no differences were observed in the macroscopic en bloc resection rate, histopathological complete resection rate, and pathological results between the groups. Adverse events did not occur in either group. CONCLUSION Local recurrence after CP was equivalent to that following HP in clinical practice. CP is useful and safe in the treatment of non-pedunculated polyps of less than 10 mm.

    DOI: 10.3748/wjg.v27.i47.8182

    Web of Science

    Scopus

    PubMed

  38. 特集 Cold polypectomyの課題 4.症例からみえた課題(1)小腸ポリープに対するcold polypectomy

    山村 健史, 中村 正直, 前田 啓子, 澤田 つな騎, 石川 恵里, 角嶋 直美, 古川 和宏, 川嶋 啓揮

    臨床消化器内科   37 巻 ( 1 ) 頁: 93 - 96   2021年12月

     詳細を見る

    出版者・発行元:日本メディカルセンター  

    DOI: 10.19020/cg.0000002065

    CiNii Research

  39. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival 査読有り 国際誌

    Yamada, K; Sawada, T; Nakamura, M; Yamamura, T; Maeda, K; Ishikawa, E; Iida, T; Mizutani, Y; Kakushima, N; Ishikawa, T; Furukawa, K; Ohno, E; Honda, T; Kawashima, H; Ishigami, M; Furune, S; Hase, T; Yokota, K; Maeda, O; Hashimoto, N; Akiyama, M; Ando, Y; Fujishiro, M

    WORLD JOURNAL OF GASTROENTEROLOGY   27 巻 ( 41 ) 頁: 7190 - 7206   2021年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:World Journal of Gastroenterology  

    BACKGROUND Despite the popularity of immune checkpoint inhibitors (ICIs) in the treatment of advanced cancer, patients often develop gastrointestinal (GI) and non-GI immune- related adverse events (irAEs). The clinical characteristics and survival outcomes of GI-irAEs have not been fully elucidated in previous reports. This necessitates the evaluation of the impact of GI-irAEs on patients receiving ICI treatment. AIM To evaluate the clinical characteristics of GI-irAEs and their impact on survival in patients treated with ICIs. METHODS In this single-center, retrospective, observational study, we reviewed the records of 661 patients who received ICIs for various cancers at Nagoya University Hospital from September 2014 to August 2020. We analyzed the clinical characteristics of patients who received ICI treatment. We also evaluated the correlation between GI-irAE development and prognosis in non-small cell lung cancer (LC) and malignant melanoma (MM). Kaplan-Meier analysis was used to compare the median overall survival (OS). Multivariate Cox proportional hazards models were used to identify prognostic factors. A P value < 0.05 was considered statistically significant. RESULTS GI-irAEs occurred in 34 of 605 patients (5.6%) treated with an anti-programmed cell death-1/programmed death-ligand 1 (anti-PD-1/PD-L1) antibody alone and in nine of 56 patients (16.1%) treated with an anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody alone or a combination of anti-PD-1 and anti-CTLA-4 antibodies. The cumulative incidence and median daily diarrhea frequency were significantly higher in patients receiving anti-CTLA-4 antibodies (P < 0.05). In 130 patients with MM, OS was significantly prolonged in the group that continued ICI treatment despite the development of GI-irAEs compared to the group that did not experience GI-irAEs (P = 0.035). In contrast, in 209 patients with non-small cell LC, there was no significant difference in OS between the groups. The multivariate analyses showed that a performance status of 2-3 (hazard ratio: 2.406; 95% confidence interval: 1.125-5.147; P = 0.024) was an independent predictive factor for OS in patients with MM. CONCLUSION Patients receiving anti-CTLA-4 antibodies develop GI-irAEs more frequently and with higher severity than those receiving anti-PD-1/PD-L1 antibodies. Continuing ICI treatment in patients with MM with GI-irAEs have better OS.

    DOI: 10.3748/wjg.v27.i41.7190

    Web of Science

    Scopus

    PubMed

  40. Endocytoscopy Is Useful for the Diagnosis of Superficial Nonampullary Duodenal Epithelial Tumors 査読有り 国際誌

    Hirose, T; Kakushima, N; Furukawa, K; Furune, S; Ishikawa, E; Sawada, T; Maeda, K; Yamamura, T; Ishikawa, T; Ohno, E; Nakamura, M; Nishida, K; Yokoi, T; Kawashima, H; Fujishiro, M

    DIGESTION   102 巻 ( 6 ) 頁: 895 - 902   2021年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Digestion  

    Introduction: Endoscopic criteria for the diagnosis of superficial nonampullary duodenal epithelial tumors (SNADETs) are lacking. The aim of this study was to explore the usefulness of endocytoscopy (ECS) in the duodenum. Methods: A total of 77 ECS images stained by methylene blue and 58 images with double staining of methylene blue and crystal violet were obtained from 20 patients. Images were classified into 3 grades based on nuclear and villi atypia: EC A, B, and C. Diagnostic performance of ECS classification to predict histology and interobserver agreement was evaluated. The performance was compared between staining methods and ×520 or ×936 zoom. Results: With methylene blue staining, high rates of accuracy, sensitivity, specificity, and positive predictive value (PPV) over 90% were achieved for tumor and nontumor diagnosis as assessed by EC A versus EC B. High rates of accuracy, sensitivity, PPV, and negative predictive value over 90% were achieved for the differentiation between the diagnosis of the Vienna category 3 and 4/5 as assessed by EC B versus C. The accuracy rate of interpreting ECS images with ×936 zoom among 10 endoscopists was 82%, and the interobserver agreement rate was 0.803 (Kendall's coefficient of concordance). In the ×936 zoom group, methylene blue staining was significantly associated with higher accuracy rate (odds ratio 1.76 [1.06-2.92], p value 0.0297). No benefit was observed by double staining. Conclusions: ECS diagnosis with methylene blue provides a high accuracy rate and good interobserver agreement to predict histology of SNADETs.

    DOI: 10.1159/000516512

    Web of Science

    Scopus

    PubMed

  41. Difference of efficacy for small bowel lesion in Crohn

    Sawada, T; Nakamura, M; Yamamura, T; Maeda, K; Ishikawa, E; Fujishiro, M

    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   36 巻   頁: 116 - 116   2021年8月

     詳細を見る

  42. Detection of Colorectal Neoplasms Using Linked Color Imaging: A Prospective, Randomized, Tandem Colonoscon Trial 査読有り 国際誌

    Hasegawa, I; Yamamura, T; Suzuki, H; Maeda, K; Sawada, T; Mizutani, Y; Ishikawa, E; Ishikawa, T; Kakushima, N; Furukawa, K; Ohno, E; Kawashima, H; Nakamura, M; Fujishiro, M

    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY   19 巻 ( 8 ) 頁: 1708 - +   2021年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Clinical Gastroenterology and Hepatology  

    Background and aims: A higher adenoma detection rate (ADR) has been shown to be related to a lower incidence and mortality of colorectal cancer. We analyzed the efficacy of linked color imaging (LCI) by assessing the detection, miss, and visibility of various featured adenomas as compared with white light imaging (WLI). Methods: This was a prospective, randomized, tandem trial. The participants were randomly assigned to 2 groups: first observation by LCI, then second observation by WLI (LCI group); or both observations by WLI (WLI group). Suspected neoplastic lesions were resected after magnifying image-enhanced endoscopy. The primary outcome was to compare the ADR during the first observation. Secondary outcomes included evaluation of adenoma miss rate (AMR) and visibility score. Results: A total of 780 patients were randomized, 700 of whom were included in the final analysis. The ADR was 69.6% and 63.2% in the LCI and WLI groups, respectively, with no significant difference. However, LCI improved the average ADR in low-detectors compared with high-detectors (76.0% vs 55.1%; P < .001). Total AMR was 20.6% in the LCI group, which was significantly lower than that in the WLI group (31.1%) (P < .001). AMR in the LCI group was significantly lower, especially for diminutive adenomas (23.4% vs 35.1%; P < .001) and nonpolypoid lesions (25.6% vs 37.9%; P < .001) compared with the WLI group. Conclusion: Although both methods provided a similar ADR, LCI had a lower AMR than WLI. LCI could benefit endoscopists with lower ADR, an observation that warrants additional study. (UMIN Clinical Trials Registry, Number: UMIN000026359).

    DOI: 10.1016/j.cgh.2021.04.004

    Web of Science

    Scopus

    PubMed

  43. An evaluation of resectability among endoscopic treatment methods for rectal neuroendocrine tumors &lt;10 mm 査読有り 国際誌

    Toriyama, K; Yamamura, T; Nakamura, M; Maeda, K; Sawada, T; Mizutani, Y; Ishikawa, E; Furukawa, K; Ishikawa, T; Ohno, E; Kawashima, H; Fujishiro, M

    ARAB JOURNAL OF GASTROENTEROLOGY   22 巻 ( 2 ) 頁: 104 - 110   2021年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Arab Journal of Gastroenterology  

    Background and Study Aims: With respect to rectal neuroendocrine tumor (NET) resection, it remains unclear which of the following methods is the most effective: conventional endoscopic mucosal resection (cEMR), EMR using a fitted cap (EMR-C), EMR with a ligation band device (EMR-L), or endoscopic submucosal dissection (ESD). Thus, in this study, we aim to retrospectively evaluate the most effective endoscopic resection for rectal NETs < 10 mm. Patients and methods: In total, 61 consecutive patients with primary rectal NETs < 10 mm in diameter were included in this study; they were then divided into three groups: those with cEMR; those with modified EMR (mEMR) involving EMR-C and EMR-L; and those with ESD. The primary endpoint was to evaluate the difference in the complete en bloc resection rate. The secondary endpoint was to investigate differences in procedure time and complications. Results: Among the three groups, a significant difference was found in procedure time (cEMR vs ESD, P < .01; mEMR vs ESD, P < .01), en bloc resection rate (cEMR vs mEMR, P = .015), tumor size (mEMR vs ESD, P < .01), percentage of tumor diameter ≥ 5 mm (mEMR vs ESD, P < .01), and complete en bloc resection rate (cEMR vs mEMR, P = .014). Meanwhile, no significant difference was noted in terms of complication rate among the three groups. Conclusion: The mEMR was the most suitable resection method for rectal NETs < 10 mm with respect to the risks and benefits from procedure-related factors, such as complete en bloc resection rate, procedure time, and complication rate.

    DOI: 10.1016/j.ajg.2021.05.007

    Web of Science

    Scopus

    PubMed

  44. Diagnostic yield of colon capsule endoscopy for Crohn's disease lesions in the whole gastrointestinal tract

    Yamada Keisaku, Nakamura Masanao, Yamamura Takeshi, Maeda Keiko, Sawada Tsunaki, Mizutani Yasuyuki, Ishikawa Eri, Ishikawa Takuya, Kakushima Naomi, Furukawa Kazuhiro, Ohno Eizaburo, Kawashima Hiroki, Honda Takashi, Ishigami Masatoshi, Fujishiro Mitsuhiro

    BMC GASTROENTEROLOGY   21 巻 ( 1 )   2021年2月

     詳細を見る

    出版者・発行元:BMC Gastroenterology  

    DOI: 10.1186/s12876-021-01657-0

    Web of Science

    Scopus

  45. Ustekinumab is effective against small bowel lesions in Crohn's disease: two case reports

    Murate Kentaro, Nakamura Masanao, Yamamura Takeshi, Maeda Keiko, Sawada Tsunaki, Mizutani Yasuyuki, Ishikawa Eri, Kakushima Naomi, Furukawa Kazuhiro, Ohno Eizaburo, Honda Takashi, Kawashima Hiroki, Ishigami Masatoshi, Fujishiro Mitsuhiro

    CLINICAL JOURNAL OF GASTROENTEROLOGY   14 巻 ( 1 ) 頁: 129 - 135   2021年2月

     詳細を見る

    出版者・発行元:Clinical Journal of Gastroenterology  

    DOI: 10.1007/s12328-020-01242-0

    Web of Science

    Scopus

  46. Gastrointestinal tract metastasis of lung cancer: The PD-L1 expression and correlated clinicopathological variables

    Ishikawa Eri, Nakaguro Masato, Nakamura Masanao, Yamamura Takeshi, Sawada Tsunaki, Mizutani Yasuyuki, Maeda Keiko, Furukawa Kazuhiro, Shimoyama Yoshie, Kawashima Hiroki, Fujishiro Mitsuhiro

    PATHOLOGY INTERNATIONAL   71 巻 ( 1 ) 頁: 33 - 41   2021年1月

     詳細を見る

    出版者・発行元:Pathology International  

    DOI: 10.1111/pin.13048

    Web of Science

    Scopus

  47. The microbiome can predict mucosal healing in small intestine in patients with Crohn's disease

    Hattori Shun, Nakamura Masanao, Yamamura Takeshi, Maeda Keiko, Sawada Tsunaki, Mizutani Yasuyuki, Yamamoto Kenta, Ishikawa Takuya, Furukawa Kazuhiro, Ohno Eizaburo, Honda Takashi, Kawashima Hiroki, Ishigami Masatoshi, Hirooka Yoshiki, Fujishiro Mitsuhiro

    JOURNAL OF GASTROENTEROLOGY   55 巻 ( 12 ) 頁: 1138 - 1149   2020年12月

     詳細を見る

    出版者・発行元:Journal of Gastroenterology  

    DOI: 10.1007/s00535-020-01728-1

    Web of Science

    Scopus

  48. Endoscopic Ultrasound Elastography as a Novel Diagnostic Method for the Assessment of Hardness and Depth of Invasion in Colorectal Neoplasms

    Esaki Masaya, Yamamura Takeshi, Nakamura Masanao, Maeda Keiko, Sawada Tsunaki, Mizutani Yasuyuki, Ishikawa Eri, Suzuki Hiroto, Kuno Takeshi, Yamada Kentaro, Hasegawa Issei, Ishikawa Takuya, Kakushima Naomi, Furukawa Kazuhiro, Ohno Eizaburo, Kawashima Hiroki, Hirooka Yoshiki, Fujishiro Mitsuhiro

    DIGESTION     2020年11月

     詳細を見る

    出版者・発行元:Digestion  

    DOI: 10.1159/000511589

    Web of Science

    Scopus

  49. Accuracy of carbon dioxide insufflation for endoscopic retrograde cholangiopancreatography using double-balloon endoscopy

    Niwa Yoshiki, Nakamura Masanao, Kawashima Hiroki, Yamamura Takeshi, Maeda Keiko, Sawada Tsunaki, Mizutani Yasuyuki, Ishikawa Eri, Ishikawa Takuya, Kakushima Naomi, Furukawa Kazuhiro, Ohno Eizaburo, Honda Takashi, Ishigami Masatoshi, Fujishiro Mitsuhiro

    WORLD JOURNAL OF GASTROENTEROLOGY   26 巻 ( 42 ) 頁: 6669 - 6678   2020年11月

     詳細を見る

    出版者・発行元:World Journal of Gastroenterology  

    DOI: 10.3748/wjg.v26.i42.6669

    Web of Science

    Scopus

  50. Endoscopic Activity and Serum TNF-alpha Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn's Disease Patients

    Murate Kentaro, Maeda Keiko, Nakamura Masanao, Sugiyama Daisuke, Wada Hirotaka, Yamamura Takeshi, Sawada Tsunaki, Mizutani Yasuyuki, Ishikawa Takuya, Furukawa Kazuhiro, Ohno Eizaburo, Honda Takashi, Kawashima Hiroki, Miyahara Ryoji, Ishigami Masatoshi, Nishikawa Hiroyoshi, Fujishiro Mitsuhiro

    INFLAMMATORY BOWEL DISEASES   26 巻 ( 11 ) 頁: 1669 - 1681   2020年11月

     詳細を見る

    出版者・発行元:Inflammatory Bowel Diseases  

    DOI: 10.1093/ibd/izaa086

    Web of Science

    Scopus

  51. Mutation analysis of gastrointestinal stromal tumors using RNA obtained via endoscopic ultrasound-guided fine-needle aspiration

    Funasaka Kohei, Miyahara Ryoji, Furukawa Kazuhiro, Sawada Tsunaki, Maeda Keiko, Yamamura Takeshi, Ishikawa Takuya, Ohno Eizaburo, Nakamura Masanao, Kawashima Hiroki, Hirooka Yoshiki, Ohmiya Naoki, Fujishiro Mitsuhiro

    TRANSLATIONAL ONCOLOGY   13 巻 ( 11 )   2020年11月

     詳細を見る

    出版者・発行元:Translational Oncology  

    DOI: 10.1016/j.tranon.2020.100848

    Web of Science

    Scopus

  52. New modality for the quantitative evaluation of tissue elasticity using a forward-viewing radial-array echoendoscope for colorectal neoplasms

    Esaki Masaya, Yamamura Takeshi, Nakamura Masanao, Maeda Keiko, Sawada Tsunaki, Mizutani Yasuyuki, Ishikawa Eri, Furukawa Kazuhiro, Kawashima Hiroki, Hirooka Yoshiki, Fujishiro Mitsuhiro

    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE     2020年10月

     詳細を見る

    出版者・発行元:International Journal of Colorectal Disease  

    DOI: 10.1007/s00384-020-03790-w

    Web of Science

    Scopus

  53. A forward-viewing radial-array echoendoscope is useful for diagnosing the depth of colorectal neoplasia invasion

    Kuno Takeshi, Yamamura Takeshi, Nakamura Masanao, Maeda Keiko, Sawada Tsunaki, Mizutani Yasuyuki, Esaki Masaya, Ishikawa Takuya, Furukawa Kazuhiro, Ohno Eizaburo, Kawashima Hiroki, Fujishiro Mitsuhiro

    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES     2020年9月

     詳細を見る

    出版者・発行元:Surgical Endoscopy  

    DOI: 10.1007/s00464-020-07936-3

    Web of Science

    Scopus

  54. 診断に苦慮した広範囲胆管癌の1例

    芳川 昌功, 川嶋 啓揮, 大野 栄三郎, 石川 卓哉, 小屋 敏也, 田中 浩敬, 酒井 大輔, 飯田 忠, 西尾 亮, 鈴木 博貴, 植月 康太, 八鹿 潤, 山田 健太, 澤田 つな騎, 前田 啓子, 山村 健史, 古川 和宏, 舩坂 好平, 中村 正直, 宮原 良二, 廣岡 芳樹

    肝胆膵治療研究会誌   16 巻 ( 1 ) 頁: 93 - 93   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:肝胆膵治療研究会  

  55. 表在型食道扁平上皮癌におけるLinked Color Imagingで観察される色情報と深達度および血管径との相関に関する検討

    小林 健一, 宮原 良二, 舩坂 好平, 古川 和宏, 澤田 つな騎, 前田 啓子, 山村 健史, 石川 卓也, 大野 栄三郎, 中村 正直, 川嶋 啓揮, 中黒 匡人, 奥村 結希, 廣岡 芳樹, 藤城 光弘

    Gastroenterological Endoscopy   62 巻 ( 9 ) 頁: 1624 - 1633   2020年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    【背景】食道扁平上皮癌の治療方針決定に正確な深達度診断が重要であるが,MM/SM1の正診率は低く解決すべき課題となっている.本研究の目的はLED光源を用いたLCIにおける食道表在癌に対する色と深達度の関連性について検討することである.【方法】表在型食道癌と診断された病変に対し白色光につづいてLCIで観察を行った.色合いの評価についてはCIE-L*a*b*空間を用いて色値を算出し,深達度ごとの癌部と非癌部の色差を算出した.血管径およびintrapapillary capillary loopの分岐角を病理的に算出し,色合いとの相関を検討した.【結果】48症例52病変が登録された.深達度別の正常と病変部の色差において,MM/SM1以深群ではEP/LPM群に比べて有意に色差が大きかった(P=0.025).血管径はb*値と弱い正の相関を認めた(相関係数=0.302,P=0.033).【結論】LED光源を用いたLCI観察は,表在型食道癌における深達度診断の向上に有用である可能性があるが,その有用性を示すのにはさらなる検討が必要である.(著者抄録)

  56. 特集 クローン病小腸狭窄病変に対する内視鏡的バルーン拡張術─基本からピットフォールまで Ⅱ.クローン病小腸狭窄病変に対するバルーン拡張術(4)クローン病におけるバルーン拡張術のコツ a.ダブルバルーン内視鏡の立場から

    中村 正直, 山村 健史, 前田 啓子, 澤田 つな騎, 水谷 泰之, 石川 恵里, 古川 和宏, 角嶋  直美, 藤城 光弘

    INTESTINE   24 巻 ( 3 ) 頁: 197 - 202   2020年8月

     詳細を見る

    出版者・発行元:日本メディカルセンター  

    DOI: 10.19020/int.0000000486

    CiNii Research

  57. 特集 分子標的時代のIBD 診療 -IBD の寛解導入,寛解維持の実践 3.IBD 治療における寛解導入と寛解維持に関するトピック(5)UC 関連腫瘍の早期診断と治療

    山村 健史, 中村 正直, 前田 啓子, 澤田 つな騎, 石川 恵里, 喜田 裕一, 古川 和宏, 川嶋 啓揮, 藤城 光弘

    臨床消化器内科   35 巻 ( 10 ) 頁: 1267 - 1273   2020年8月

     詳細を見る

    出版者・発行元:日本メディカルセンター  

    DOI: 10.19020/cg.0000001325

    CiNii Research

  58. Subjective Symptoms in Patients with Eosinophilic Esophagitis Are Related to Esophageal Wall Thickness and Esophageal Body Pressure.

    Muroi K, Kakushima N, Furukawa K, Ishikawa E, Sawada T, Ishikawa T, Maeda K, Yamamura T, Ohno E, Nakamura M, Kawashima H, Funasaka K, Miyahara R, Fujishiro M

    Digestive diseases and sciences     2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s10620-020-06527-5

    PubMed

  59. Filtrated Adipose Tissue-Derived Mesenchymal Stem Cell Lysate Ameliorates Experimental Acute Colitis in Mice

    Nishikawa Takahiro, Maeda Keiko, Nakamura Masanao, Yamamura Takeshi, Sawada Tsunaki, Mizutani Yasuyuki, Ito Takanori, Ishikawa Takuya, Furukawa Kazuhiro, Ohno Eizaburo, Miyahara Ryoji, Kawashima Hiroki, Honda Takashi, Ishigami Masatoshi, Yamamoto Tokunori, Matsumoto Seiji, Hotta Yuji, Fujishiro Mitsuhiro

    DIGESTIVE DISEASES AND SCIENCES     2020年6月

     詳細を見る

    出版者・発行元:Digestive Diseases and Sciences  

    DOI: 10.1007/s10620-020-06359-3

    Web of Science

    Scopus

  60. Clinical Factors Associated with Missing Colorectal Polyp on Colon Capsule Endoscopy

    Yamada Keisaku, Nakamura Masanao, Yamamura Takeshi, Maeda Keiko, Sawada Tsunaki, Mizutani Yasuyuki, Ishikawa Takuya, Furukawa Kazuhiro, Ohno Eizaburo, Miyahara Ryoji, Kawashima Hiroki, Hotta Naoki, Hirooka Yoshiki

    DIGESTION   101 巻 ( 3 ) 頁: 316-322   2020年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1159/000498942

    Web of Science

    Scopus

    PubMed

  61. Double-balloon endoscopic retrograde cholangiopancreatography for patients who underwent liver operation: A retrospective study

    Nishio Ryo, Kawashima Hiroki, Nakamura Masanao, Ohno Eizaburo, Ishikawa Takuya, Yamamura Takeshi, Maeda Keiko, Sawada Tsunaki, Tanaka Hiroyuki, Sakai Daisuke, Miyahara Ryoji, Ishigami Masatoshi, Hirooka Yoshiki, Fujishiro Mitsuhiro

    WORLD JOURNAL OF GASTROENTEROLOGY   26 巻 ( 10 ) 頁: 1056 - 1066   2020年3月

     詳細を見る

    出版者・発行元:World Journal of Gastroenterology  

    DOI: 10.3748/wjg.v26.i10.1056

    Web of Science

    Scopus

  62. Usefulness of Endoscopic Ultrasound Elastography Combined With the Strain Ratio in the Estimation of Treatment Effect in Autoimmune Pancreatitis

    Ishikawa Takuya, Kawashima Hiroki, Ohno Eizaburo, Tanaka Hiroyuki, Maeda Keiko, Sawada Tsunaki, Yamamura Takeshi, Furukawa Kazuhiro, Nakamura Masanao, Miyahara Ryoji, Ishigami Masatoshi, Fujishiro Mitsuhiro

    PANCREAS   49 巻 ( 2 ) 頁: E21 - E22   2020年2月

     詳細を見る

    出版者・発行元:Pancreas  

    DOI: 10.1097/MPA.0000000000001481

    Web of Science

    Scopus

  63. Color information from linked color imaging is associated with invasion depth and vascular diameter in superficial esophageal squamous cell carcinoma

    Kobayashi Kenichi, Miyahara Ryoji, Funasaka Kohei, Furukawa Kazuhiro, Sawada Tsunaki, Maeda Keiko, Yamamura Takeshi, Ishikawa Takuya, Ohno Eizaburo, Nakamura Masanao, Kawashima Hiroki, Nakaguro Masato, Okumura Yuki, Hirooka Yoshiki, Fujishiro Mitsuhiro

    DIGESTIVE ENDOSCOPY   32 巻 ( 1 ) 頁: 65 - 73   2020年1月

     詳細を見る

    出版者・発行元:Digestive Endoscopy  

    DOI: 10.1111/den.13469

    Web of Science

    Scopus

  64. Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis

    Nakamura Masanao, Yamamura Takeshi, Maeda Keiko, Sawada Tsunaki, Mizutani Yasuyuki, Ishikawa Eri, Ohashi Ayako, Kajikawa Go, Furukawa Kazuhiro, Ohno Eizaburo, Honda Takashi, Kawashima Hiroki, Ishigami Masatoshi, Fujishiro Mitsuhiro

    INTERNAL MEDICINE   59 巻 ( 23 ) 頁: 3009 - 3014   2020年

     詳細を見る

    出版者・発行元:Internal Medicine  

    DOI: 10.2169/internalmedicine.5302-20

    Web of Science

    Scopus

  65. Comparison of high-resolution manometry in patients complaining of dysphagia among patients with or without diabetes mellitus

    Muroi K.

    Digestion     2020年

     詳細を見る

    出版者・発行元:Digestion  

    DOI: 10.1159/000510081

    Scopus

  66. A Prospective Study of Factors Associated with Abdominal Pain in Patients during Unsedated Colonoscopy Using a Magnifying Endoscope

    Suzuki Hiroto, Nakamura Masanao, Yamamura Takeshi, Maeda Keiko, Sawada Tsunaki, Mizutani Yasuyuki, Ishikawa Takuya, Furukawa Kazuhiro, Ohno Eizaburo, Honda Takashi, Kawashima Hiroki, Ishigami Masatoshi, Fujishiro Mitsuhiro

    INTERNAL MEDICINE   59 巻 ( 15 ) 頁: 1795 - 1801   2020年

     詳細を見る

    出版者・発行元:Internal Medicine  

    DOI: 10.2169/internalmedicine.4267-19

    Web of Science

    Scopus

  67. 単発性小腸Peutz-Jeghers型ポリープに関する臨床的検討

    鳥山 和浩, 中村 正直, 山村 健史, 前田 啓子, 澤田 つな騎, 水谷 泰之, 石川 恵里, 梶川 豪, 村手 健太郎, 喜田 裕一, 江崎 正哉, 濱崎 元伸, 角嶋 直美, 古川 和宏, 藤城 光弘

    日本小腸学会学術集会プログラム・抄録集   4 巻 ( 0 ) 頁: 39 - 39   2020年

     詳細を見る

    記述言語:日本語   出版者・発行元:日本小腸学会  

    <p>【背景】Peutz-Jeghers症候群(PJS)は食道を除く全消化管において上皮の過形成と粘膜筋板のポリープ内への樹枝状増生を特徴とする過誤腫性ポリポーシスと皮膚、粘膜の色素斑を特徴とする常染色体優性遺伝性疾患である。一方、家族歴や皮膚、粘膜の色素沈着を伴わない単発性のPeutz-Jeghers型ポリープ(PJP)を認めることがあるが、その臨床的特徴に関する報告は少ないのが現状である。</p><p>【目的】単発性小腸PJPにおける臨床的特徴を明らかにする。</p><p>【対象】2007年4月から2020年5月までに当院で内視鏡治療を施行し、病理組織学的にPJPと診断された単発性小腸PJP16症例。</p><p>【結果】レトロスペクティブにカルテ、内視鏡画像をレビューした。性別は男性10例、女性6例、診断時年齢中央値(範囲)は61(18-82)歳。診断契機は貧血7例、黒色便5例、腹痛1例、イレウス症状1例、他疾患精査時の偶発的発見が2例。原発部位は空腸14例、回腸2例で、腫瘍径中央値(範囲)は25(4-35)mm。切除したPJP全病変で病変内に悪性腫瘍の併存は認めなかった。癌の既往歴を有したのは6例(前立腺癌2例、舌癌1例、大腸癌1例、胃癌1例、子宮体癌1例)。観察期間中央値(範囲)は4.6(0.1-53.7)ヶ月で再発並びに関連死は認めなかった。</p><p>【考察】単発性小腸PJPにおいては診断時の年齢が高く、発見契機としては出血関連症状が多く、病変部位は空腸に多い特徴があった。</p><p>【結語】当院で経験した単発性小腸PJPの臨床的特徴を検討した。今後更なる症例の蓄積が必要である。</p>

    DOI: 10.32264/shocho.4.0_39

    CiNii Research

  68. Specific members of gut microbiota predict mucosal healing in Crohn's disease

    Hattori S., Nakamura M., Yamamura T., Maeda K., Sawada T., Mizutani Y., Yamamoto K., Pu L. Zorron Cheng Tao, Honda T., Ishikawa T., Furukawa K., Ohno E., Miyahara R., Kawashima H., Fujishiro M.

    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   34 巻   頁: 152 - 152   2019年9月

     詳細を見る

  69. Objective evaluation of the therapeutic effect of ustekinumab on Crohn's disease

    Yamamura, T; Nakamura, M; Murate, K; Maeda, K; Sawada, T; Mizutani, Y; Nishikawa, T; Hattori, S; Yamamoto, K; Pu, LZCT; Ishikawa, T; Furukawa, K; Ohno, E; Miyahara, R; Kawashima, H; Fujishiro, M

    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY   34 巻   頁: 145 - 145   2019年9月

     詳細を見る

  70. Roles of the mesenchymal stromal/stem cell marker meflin in cardiac tissue repair and the development of diastolic dysfunction

    Hara A.

    Circulation Research   125 巻 ( 4 ) 頁: 414 - 430   2019年8月

     詳細を見る

    出版者・発行元:Circulation Research  

    DOI: 10.1161/CIRCRESAHA.119.314806

    Scopus

  71. USEFULNESS OF THE FORWARD-VIEWING RADIAL-ARRAY ECHOENDOSCOPE IN THE DIAGNOSIS OF INVASION DEPTH OF COLORECTAL NEOPLASIA 査読有り 国際誌

    Kuno Takeshi, Yamamura Takeshi, Nakamura Masanao, Maeda Keiko, Sawada Tsunaki, Mizutani Yasuyuki, Suzuki Hiroto, Esaki Masaya, Ishikawa Takuya, Furukawa Kazuhiro, Ohno Eizaburo, Kawashima Hiroki, Miyahara Ryoji, Hirooka Yoshiki

    GASTROINTESTINAL ENDOSCOPY   89 巻 ( 6 ) 頁: AB324 - AB324   2019年6月

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    Web of Science

  72. ダブルバルーン小腸内視鏡を用いた硬化療法にて治療効果を得た小腸多発血管腫の1例

    山田 啓策, 山村 健史, 中村 正直, 澤田 つな騎, 水谷 泰之, 前田 啓子, 古川 和宏, 宮原 良二, 横井 太紀雄, 廣岡 芳樹

    Gastroenterological Endoscopy   61 巻 ( 6 ) 頁: 1231 - 1236   2019年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    70歳代男性。1ヵ月間持続する黒色便にて当科紹介となった。上下部消化管内視鏡検査では、明らかな出血源を認めなかった。小腸出血を疑いカプセル内視鏡検査を施行したところ、全小腸にわたり多発する隆起性病変を認めた。ダブルバルーン小腸内視鏡検査を行いジャンボバイオプシー目的の内視鏡的粘膜切除術(Endoscopic mucosal resection:EMR)にて海綿状血管腫と診断した。後日多発する血管腫に対してpolidocanol(Aethoxysklerol)による硬化療法を行った。4日後の内視鏡観察では、血管腫は縮小を認め、以後黒色便も消失した。小腸に多発する血管腫に対して内視鏡的硬化療法が有用であった1例を経験したので報告する。(著者抄録)

  73. CLINICAL SIGNIFICANCE OF THE PATENCY OF GASTROINTESTINAL TRACT IN CROHN'S DISEASE EVALUATED BY PATENCY CAPSULE

    Nakamura, M; Yamamura, T; Maeda, K; Sawada, T; Mizutani, Y; Kuno, T; Yamada, K; Ishikawa, T; Furukawa, K; Ohno, E; Miyahara, R; Kawashima, H; Hirooka, Y

    GASTROINTESTINAL ENDOSCOPY   89 巻 ( 6 ) 頁: AB333 - AB333   2019年6月

  74. FACTORS RELATED TO MISSED COLORECTAL POLYPS ON COLON CAPSULE ENDOSCOPY IN CLINICAL PRACTICE

    Yamada, K; Nakamura, M; Yamamura, T; Maeda, K; Sawada, T; Mizutani, Y; Niwa, Y; Ishikawa, E; Otsuka, H; Suzuki, H; Ishikawa, T; Furukawa, K; Ohno, E; Miyahara, R; Kawashima, H; Hotta, N; Pu, LZCT; Hirooka, Y

    GASTROINTESTINAL ENDOSCOPY   89 巻 ( 6 ) 頁: AB155 - AB155   2019年6月

  75. 今月の主題 知っておきたい小腸疾患 主題 小腸の非腫瘍性疾患-小腸リンパ管拡張症

    中村 正直, 山村 健史, 前田 啓子, 澤田 つな騎, 水谷 泰之, 丹羽 慶樹, 石川 恵里, 大塚 裕之, 鈴木 悠土, 西川 貴広, 石田 哲也, 久野 剛史, 服部 峻, 山田 啓策, 廣岡 芳樹, 藤城 光弘

    胃と腸   54 巻 ( 4 ) 頁: 532 - 536   2019年4月

     詳細を見る

    出版者・発行元:株式会社医学書院  

    DOI: 10.11477/mf.1403201630

    CiNii Research

  76. Utility of linked color imaging for endoscopic diagnosis of early gastric cancer

    Fujiyoshi Toshihisa, Miyahara Ryoji, Funasaka Kohei, Furukawa Kazuhiro, Sawada Tsunaki, Maeda Keiko, Yamamura Takeshi, Ishikawa Takuya, Ohno Eizaburo, Nakamura Masanao, Kawashima Hiroki, Nakaguro Masato, Nakatochi Masahiro, Hirooka Yoshiki

    WORLD JOURNAL OF GASTROENTEROLOGY   25 巻 ( 10 ) 頁: 1248-1258   2019年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3748/wjg.v25.i10.1248

    Web of Science

    Scopus

    PubMed

  77. A case of multiple hemangiomas of the small intestine treated by sclerotherapy using double-balloon enteroscopy

    Yamada K.

    Gastroenterological Endoscopy   61 巻 ( 6 ) 頁: 1231 - 1236   2019年

     詳細を見る

    出版者・発行元:Gastroenterological Endoscopy  

    DOI: 10.11280/gee.61.1231

    Scopus

  78. Lewis Score on Capsule Endoscopy as a Predictor of the Risk for Crohn's Disease-Related Emergency Hospitalization and Clinical Relapse in Patients with Small Bowel Crohn's Disease

    Nishikawa Takahiro, Nakamura Masanao, Yamamura Takeshi, Maeda Keiko, Sawada Tsunaki, Mizutani Yasuyuki, Ishikawa Takuya, Furukawa Kazuhiro, Ohno Eizaburo, Miyahara Ryoji, Kawashima Hiroki, Hirooka Yoshiki

    GASTROENTEROLOGY RESEARCH AND PRACTICE   2019 巻   頁: 4274257   2019年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1155/2019/4274257

    Web of Science

    Scopus

    PubMed

  79. 腸リンパ管拡張症の診断と治療

    中村 正直, 山村 健史, 前田 啓子, 澤田 つな騎, 水谷 泰之, 藤城 光弘

    日本小腸学会学術集会プログラム・抄録集   3 巻 ( 0 ) 頁: 34_2 - 34_2   2019年

     詳細を見る

    記述言語:日本語   出版者・発行元:日本小腸学会  

    <p>【背景・目的】 小腸内視鏡診断の進歩により腸リンパ管拡張症(Intestinal lymphangiectasia:IL)を含む蛋白漏出性腸症の小腸精査が可能になった。本研究の目的はILの臨床経過を後ろ向きに評価し、その特徴を明らかにしたうえでより良い治療法を模索することであった。</p><p>【対象と方法】 対象は2003年6月から2019年6月までにILと診断された17例(男性9例、女性8例、発症年齢は中央値37歳、0-75歳)であった。ILの診断は蛋白漏出性腸症と診断され且つ内視鏡下生検もしくは剖検にて病理学的に腸リンパ管拡張を認めたもので、他疾患が否定的であったものとした。白色絨毛、散布性白点を有する白色絨毛群(WV)と、異常なしもしくは軽度絨毛腫大、ケルクリング襞腫大を認める非白色絨毛群(NWV)に分けて臨床成績を比較検討した。</p><p>【結果】 WV、NWVは10例、7例であった。平均血清アルブミン値(g/dl)はWV:NWV = 2.0:1.2でNWVにおいて有意に低かった(P = 0.0061)。平均<i>α</i>1アンチトリプシンクリアランスはWV:NWV = 132:284(P = 0.0509)であった。ステロイド治療への反応はWV:NWV = 2/7:6/6 例でみられた。平均観察期間48箇月において1例のILが影響した死亡例を経験したが、重篤な真菌感染症によるものであった。</p><p>【結論】 NWV群は蛋白漏出は多いがステロイドへの反応がWV群よりも良好であった。治療のゴールドスタンダードは存在せず可能な可能で効果があるものを続けることが現状であった。</p>

    DOI: 10.32264/shocho.3.0_34_2

    CiNii Research

  80. Validity of Capsule Endoscopy in Monitoring Therapeutic Interventions in Patients with Crohn's Disease. 査読有り

    Journal of clinical medicine   7 巻 ( 10 )   2018年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3390/jcm7100311

    PubMed

  81. クローン病小腸術後患者に対するエレンタールの使用効果と内視鏡診断

    中村 正直, 山村 健史, 前田 啓子, 澤田 つな騎, 水谷 泰之, 石川 卓哉, 古川 和宏, 舩坂 好平, 大野 栄三郎, 川嶋 啓揮, 宮原 良二, 廣岡 芳樹

    Biomedical Research on Trace Elements   29 巻 ( 1 ) 頁: 50 - 51   2018年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本微量元素学会  

  82. Identification of Meflin as a Potential marker for mesenchymal stromal cells 査読有り

    Maeda K, Enomoto A, Hara A, Asai N, Kobayashi T, Horinouchi A, Maruyama S, Ishikawa Y, Nishiyama T, Kiyoi H, Kato T, Ando K, Weng L, Mii S, Asai M, Mizutani Y, Watanabe O, Hirooka Y, Goto H, Takahashi M

    Scientific Reports     2016年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/srep22288

  83. Azathioprine is essential following cyclosporine for patients with steroid-refractory ulcerative colitis 査読有り

    Miyake N, Ando T, Ishiguro K, Maeda O, Watanabe O, Hirayama Y, Maeda K, Morise K, Matsushita M, Furukawa K, Funasaka K, Nakamura M, Miyahara R, Ohmiya N, Goto H.

    World J Gastroenterol     2015年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3748/wjg.v21.i1.254

  84. Usefulness of Helicobacter pylori eradication for precancerous lesions of the gastric remnant 査読有り

    Sakakibara M, Ando T, Ishiguro K, Maeda O, Watanabe O, Hirayama Y, Morise K, Maeda K, Matsushita M, Furukawa K, Funasaka K, Nakamura M, Miyahara R, Goto H

    J Gastroenterol Hepatol     2014年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/jgh.12772

  85. Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis. 査読有り

    Mimura S, Ando T, Ishiguro K, Maeda O, Watanabe O, Ujihara M, Hirayama Y, Morise K, Maeda K, Matsushita M, Funasaka K, Nakamura M, Miyahara R, Ozaki N, Goto H.

    Scand J Gastroenterol     2013年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.3109/00365521.2013.832366

  86. Significance of cancer-associated fibroblasts in the regulation of gene expression in the leading cells of invasive lung cancer. 査読有り

    An J, Enomoto A, Weng L, Kato T, Iwakoshi A, Ushida K, Maeda K, Ishida-Takagishi M, Ishii G, Ming S, Sun T, Takahashi M

    J Cancer Res Clin Oncol     2013年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00432-012-1328-6

▼全件表示

MISC 16

  1. 特集 IBD診療-ますます増えた薬剤の選択とさらなる進化の展望 1.治療薬の使い分けの総論と各論(4)中等症UCにおけるバイオ製剤/JAK阻害薬の使い分け-抗IL-23抗体も含めて

    中村 正直, 山村 健史, 前田 啓子, 澤田 つな騎, 石川 恵里, 川嶋 啓揮  

    臨床消化器内科39 巻 ( 2 ) 頁: 140 - 146   2024年1月

     詳細を見る

    出版者・発行元:日本メディカルセンター  

    DOI: 10.19020/cg.0000002926

    CiNii Research

  2. 腸管上皮細胞は、病原体の接着を認識し、エンドソームの機能調節を介して、侵入を阻害する

    前田啓子, Wayne I Lencer  

    実験医学   2022年8月

  3. 特集 小腸内視鏡が変えた疾患マネージメント 小腸疾患に対するアプローチ

    中村 正直, 大宮 直木, 山村 健史, 前田 啓子, 澤田 つな騎, 石川 恵里  

    消化器内視鏡33 巻 ( 12 ) 頁: 1792 - 1798   2021年12月

     詳細を見る

    出版者・発行元:(株)東京医学社  

    DOI: 10.24479/j02312.2022082023

    CiNii Research

  4. Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis 査読有り

    Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa E, Ohashi A, Kajikawa G, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Fujishiro M  

    Internal medicine (Tokyo, Japan)   2020年7月

     詳細を見る

    記述言語:英語  

    DOI: 10.2169/internalmedicine.5302-20

    PubMed

  5. Use of Immunostaining for the diagnosis of Lymphovascular invasion in superficial Barrett's esophageal adenocarcinoma. 査読有り

    Hosono I, Miyahara R, Furukawa K, Funasaka K, Sawada T, Maeda K, Yamamura T, Ishikawa T, Ohno E, Nakamura M, Kawashima H, Yokoi T, Tsukamoto T, Hirooka Y, Fujishiro M  

    BMC gastroenterology20 巻 ( 1 ) 頁: 175   2020年6月

     詳細を見る

    記述言語:英語  

    DOI: 10.1186/s12876-020-01319-7

    PubMed

  6. Filtrated Adipose Tissue-Derived Mesenchymal Stem Cell Lysate Ameliorates Experimental Acute Colitis in Mice 査読有り

    Nishikawa T, Maeda K, Nakamura M, Yamamura T, Sawada T, Mizutani Y, Ito T, Ishikawa T, Furukawa K, Ohno E, Miyahara R, Kawashima H, Honda T, Ishigami M, Yamamoto T, Matsumoto S, Hotta Y, Fujishiro M  

    Digestive diseases and sciences   2020年6月

     詳細を見る

    記述言語:英語  

    DOI: 10.1007/s10620-020-06359-3

    PubMed

  7. Endoscopic Activity and Serum TNF-α Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn’s Disease Patients 査読有り

    Murate K, Maeda K, Nakamura M, Sugiyama D, Wada H, Yamamura T, Sawada T, Mizutani Y, Ishikawa T, Furukawa K, Ohno E, Honda T, Kawashima H, Miyahara R, Ishigami M, Nishikawa H, Fujishiro M  

    Inflammatory bowel diseases   2020年5月

     詳細を見る

    記述言語:英語  

    DOI: 10.1093/ibd/izaa086

    PubMed

  8. Double-balloon endoscopic retrograde cholangiopancreatography for patients who underwent liver operation: A retrospective study 査読有り

    Nishio R, Kawashima H, Nakamura M, Ohno E, Ishikawa T, Yamamura T, Maeda K, Sawada T, Tanaka H, Sakai D, Miyahara R, Ishigami M, Hirooka Y, Fujishiro M  

    World journal of gastroenterology26 巻 ( 10 ) 頁: 1056-1066   2020年3月

     詳細を見る

    記述言語:英語  

    DOI: 10.3748/wjg.v26.i10.1056

    PubMed

  9. Usefulness of Endoscopic Ultrasound Elastography Combined With the Strain Ratio in the Estimation of Treatment Effect in Autoimmune Pancreatitis 査読有り

    Ishikawa T, Kawashima H, Ohno E, Tanaka H, Maeda K, Sawada T, Yamamura T, Furukawa K, Nakamura M, Miyahara R, Ishigami M, Fujishiro M  

    Pancreas49 巻 ( 2 ) 頁: e21-e22   2020年2月

     詳細を見る

    記述言語:英語  

    DOI: 10.1097/MPA.0000000000001481

    PubMed

  10. Color information from linked color imaging is associated with invasion depth and vascular diameter in superficial esophageal squamous cell carcinoma 査読有り

    Kobayashi K, Miyahara R, Funasaka K, Furukawa K, Sawada T, Maeda K, Yamamura T, Ishikawa T, Ohno E, Nakamura M, Kawashima H, Nakaguro M, Okumura Y, Hirooka Y, Fujishiro M  

    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society32 巻 ( 1 ) 頁: 65-73   2020年1月

     詳細を見る

    記述言語:英語  

    DOI: 10.1111/den.13469

    PubMed

  11. A Prospective Study of Factors Associated with Abdominal Pain in Patients during Unsedated Colonoscopy Using a Magnifying Endoscope 査読有り

    Suzuki H, Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa T, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Fujishiro M  

    Internal medicine (Tokyo, Japan)59 巻 ( 15 ) 頁: 1795-1801   2020年

     詳細を見る

    記述言語:英語  

    DOI: 10.2169/internalmedicine.4267-19

    PubMed

  12. Roles of the Mesenchymal Stromal/Stem Cell Marker Meflin in Cardiac Tissue Repair and the Development of Diastolic Dysfunction 査読有り

    Hara A, Kobayashi H, Asai N, Saito S, Higuchi T, Kato K, Okumura T, Bando YK, Takefuji M, Mizutani Y, Miyai Y, Saito S, Maruyama S, Maeda K, Ouchi N, Nagasaka A, Miyata T, Mii S, Kioka N, Worthley DL, Murohara T, Takahashi M, Enomoto A  

    Circulation research125 巻 ( 4 ) 頁: 414-430   2019年8月

     詳細を見る

    記述言語:英語  

    DOI: 10.1161/CIRCRESAHA.119.314806

    PubMed

  13. 【消化管疾患と緊急内視鏡】消化器疾患における緊急内視鏡の果たす役割

    古根 聡, 古川 和宏, 宮原 良二, 伊藤 隆徳, 澤田 つな騎, 前田 啓子, 山村 健史, 石川 卓哉, 石津 洋二, 大野 栄三郎, 中村 正直, 本多 隆, 石上 雅敏, 川嶋 啓揮, 藤城 光弘  

    消化器・肝臓内科6 巻 ( 1 ) 頁: 1 - 6   2019年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

  14. 【原因不明消化管出血(OGIB)】緊急カプセル内視鏡・バルーン内視鏡を可能にする体制作りと実際の運用

    山村 健史, 中村 正直, 前田 啓子, 澤田 つな騎, 古川 和宏, 宮原 良二, 川嶋 啓揮, 藤城 光弘  

    Intestine23 巻 ( 4 ) 頁: 351 - 356   2019年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)日本メディカルセンター  

    <文献概要>小腸疾患の内視鏡診断はバルーン内視鏡(balloon-assisted endoscopy;BAE)や小腸カプセル内視鏡(small bowel capsule endoscopy;SBCE)など検査デバイスの発展により,飛躍的に向上した.それに伴い原因不明の消化管出血であるOGIB(obscure gastrointestinal bleeding)に関する論文も多く報告されるようになり,その全貌が明らかになってきている.かつて外科的手術や血管内放射線治療が必要とされた小腸出血は,内視鏡的に止血が可能になっており,患者への侵襲も少なく済むようになった.本邦では2015年にOBIGにおける診断アルゴリズムも提唱され,診断や治療方針の参考にされている.実際の診断時には,検査時期や病変の種類が病変発見成功の鍵を握っているが,現状ではその体制や運用の方法は各施設に委ねられている.今後,OGIBの診療を広めていくためには,検査の運用や体制作りも非常に重要になってくる.本稿では当院におけるOGIB時のBAEやSBCEの検査体制や運用方法について記載する.

  15. Hepatic portal venous gas following colonoscopy in a patient with Crohn's disease. 査読有り

    Ujihara M, Ando T, Ishiguro K, Maeda O, Watanabe O, Hirayama Y, Maeda K, Morise K, Matsushita M, Funasaka K, Nakamura M, Miyahara R, Ohmiya N, Goto H  

    Nagoya journal of medical science75 巻 ( 3-4 ) 頁: 273-8   2013年8月

     詳細を見る

    記述言語:英語  

    PubMed

  16. Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis. 査読有り

    Ujihara M, Ando T, Ishiguro K, Maeda O, Watanabe O, Hirayama Y, Morise K, Maeda K, Matsushita M, Miyahara R, Ohmiya N, Nishio Y, Yamaguchi T, Haruta J, Ina K, Goto H  

    BMC research notes6 巻   頁: 210   2013年5月

     詳細を見る

    記述言語:英語  

    DOI: 10.1186/1756-0500-6-210

    PubMed

▼全件表示

講演・口頭発表等 8

  1. PARD6Bによる腸管上皮細胞の新たな防御機構の同定

    前田啓子, 中村正直, 藤城光弘

    消化器病学会総会 

     詳細を見る

    開催年月日: 2019年5月

    記述言語:英語   会議種別:シンポジウム・ワークショップ パネル(公募)  

    開催地:石川県   国名:日本国  

  2. Innate Host Defense at Mucosal Surfaces by Rapid Degradation of Pard6B and Apkc to Deplete the Apical Endosome 国際会議

    Keiko Maeda, Nicholas Zachos, and Wayne I Lencer

     詳細を見る

    開催年月日: 2018年6月

    記述言語:英語   会議種別:口頭発表(一般)  

    国名:アメリカ合衆国  

  3. Only the PARD6B Paralogue of the PARD6 Polarity Protein Family Regulates the Apical Endosomal Compartment of Canine MDCK Epithelial Cells 国際会議

    Keiko Maeda, Wayne I Lencer

     詳細を見る

    開催年月日: 2017年5月

    記述言語:英語   会議種別:ポスター発表  

    国名:アメリカ合衆国  

  4. クローン病におけるustekinumabの治療効果および予後予測因子の検討

    村手健太郎、前田啓子、藤代光弘

    日本消化器病学会総会  2021年4月 

  5. 潰瘍性大腸炎の内視鏡的活動性と粘膜治癒を反映するバイオマーカーの同定

    前田啓子, 中村正直, 藤代光弘

    日本消化器病学会総会  2022年4月22日 

  6. Monoclonal antibody against neoepitope of caspase-cleaved mature interleukin-18 ameliorates colitis and improve barrier function

    Keiko Maeda, Masanao Nakamura, Masatoshi Ishigami

    Digestive Disease Week 2023  2023年5月8日 

  7. 女性医師の多様な働き方とキャリアプラン

    前田啓子

    日本消化器病学会総会  2022年4月22日 

  8. 炎症性腸疾患に対する新規インフラマソーム標的治療法の開発

    池上修二, 前田啓子, 藤代光弘

    日本消化器関連学会週間(JDDW)  2021年11月27日 

▼全件表示

共同研究・競争的資金等の研究課題 8

  1. 腸管上皮細胞の防御機構の解明と治療応用

    2023年4月 - 2025年3月

    日本女医会 

  2. 腸管上皮細胞の抗原認識機構の解明と炎症性腸疾患への治療応用

    2023年4月 - 2025年3月

    日本炎症性腸疾患学会 

  3. 炎症性腸疾患の多様化を見据えた新規インフラマソーム標的治療法の開発

    2021年4月 - 2022年3月

    国立研究開発法人 日本医療研究開発機構  国立研究開発法人 日本医療研究開発機構 

      詳細を見る

    担当区分:研究代表者 

  4. 腸管上皮細胞の抗原認識機構の解明と治療応用

    日東学術振興財団 

      詳細を見る

    担当区分:研究代表者 

  5. 腸管上皮細胞の防御機構の解明と治療応用

    武田科学振興財団 

      詳細を見る

    担当区分:研究代表者 

  6. Disentangling underlying mechanism of cross-talk between the gut-brain axis to influence brain behavior functionality

    国立研究開発法人 日本医療研究開発機構 

      詳細を見る

    担当区分:研究代表者 

  7. 新しい動物モデルを用いた炎症性腸疾患の病態解明と 新規治療法の探索

    公益財団法人豊秋奨学会 

      詳細を見る

    担当区分:研究代表者 

  8. 腸管上皮細胞の抗原認識機構の解明

    愛知健康増進財団 

      詳細を見る

    担当区分:研究代表者 

▼全件表示

科研費 2

  1. Elucidation of the cell-autonomous host defense at mucosal ssurfaces in rotavirus infection

    2024年9月 - 2026年3月

    国立研究開発法人 日本医療研究開発機構 

  2. 炎症性腸疾患の多様化を見据えた新規インフラマソーム標的治療法の開発

    研究課題/研究課題番号:21K15920  2021年4月 - 2024年3月

    日本学術振興会  科学研究費助成事業  若手研究

    前田 啓子

      詳細を見る

    担当区分:研究代表者 

    配分額:4160000円 ( 直接経費:3200000円 、 間接経費:960000円 )

    近年、IBD患者の急増とともに、既存治療に対する一次、二次無効を呈する難治例が増加し、病態に応じた治療戦略の確立が急務となっている。その病態には粘膜免疫の破綻、腸内細菌叢の関与とともに、両者を制御するインフラマソーム経路の重要性が認識されてきている。申請者は、治療抵抗性のIBD患者の血液、腸管組織においてインフラマソーム関連サイトカインの発現が上昇することを見出した。IL-18が高発現する患者群の粘膜関連細菌叢、NLRP3、NLRC4遺伝子変異、臨床情報を解析し、特徴を明らかにすることは、IL-18が病態の主軸となる患者群の特定、そして病態に応じた治療応用につながると考えられる。
    近年、炎症性腸疾患(IBD)患者の急増とともに、既存治療に対する一次、二次無効を呈する難治例が増加し、病態に応じた治療戦略の確立が急務となっている。その病態には粘膜免疫の破綻、腸内細菌叢の関与とともに、両者を制御するインフラマソーム経路の重要性が認識されてきている。研究代表者は、治療抵抗性のIBD患者の血液、腸管組織においてインフラマソーム関連サイトカインであるインターロイキン-18(IL-18)の発現の上昇を見出した。加えて、抗マウスIL-18中和抗体の投与により、腸内細菌叢の変化、Th1経路の抑制を介して、IBDモデルマウスの腸炎が改善するという知見を得た。研究代表者らは、これらの結果をもとに、より高い特異性・より長い半減期を持つ抗ヒト活性型IL-18モノクローナル中和抗体を開発した。抗ヒトIL-18中和抗体はマウスIL-18と結合し、マウス細胞株P815 において、IL-18にて産生が誘導されるCXCL-2の分泌を、用量依存的に抑制する結果を得ている 。マウスIL-18機能も抑制することから、IBDモデルマウスを用いた評価が可能である。また、抗ヒトIL-18中和抗体は、カニクイザルIL-18と結合することも同定している。
    今年度は、抗IL-18抗体の投与にて2種類の腸炎モデルマウスの炎症を抑制することを同定した。また、既存治療との併用にてより優位に腸炎抑制効果があることを見出した。現在は、抗ヒトIL-18抗体の炎症抑制効果をヒト腸管オルガノイド、カニクイザルを用いて実験を行い、抗ヒトIL-18抗体の安全性の確認、有効容量の設定を検討している。
    作成した抗活性型IL-18抗体は、2種類の腸炎モデルマウスへの投与を行ったところ、有意な腸炎抑制効果を認めた。腸炎抑制の機序としては、腸管上皮細胞のバリア機能の改善、Th1経路の抑制、腸内細菌叢の変化を誘導することを同定した。また、既存治療との併用にて相乗して腸炎抑制効果を認めることを同定した。
    <BR>
    現在は、抗ヒトIL-18抗体の安全性、腸炎抑制効果の評価のため、ヒトと活性型IL-18の断端が同じであるカニクイザルに投与を行い、安全性の評価、また腸炎モデルでの治療効果について検討を行う予定である。おおむね計画通りに進行している。
    今後は抗ヒトIL-18抗体の炎症抑制効果をヒト腸管オルガノイド、カニクイザルを用いて実験を行い、抗ヒトIL-18抗体の安全性の確認、有効容量の設定を行う、また、当院のIBDデータベースを利用した血清IL-18高発現群の予後、臨床的特徴、インフラマソームの構成分子であるNLRP3、NLRC4遺伝子変異、粘膜関連細菌叢の解析を行う。

産業財産権 2

  1. 炎症性腸疾患の活動性バイオマーカーの同定

    前田啓子, 中村正直, 石上雅敏

     詳細を見る

    出願番号:特願2022-036955  出願日:2022年1月

  2. 間葉系幹細胞とペリサイトの新規マーカーの同定

    榎本篤、前田啓子、高橋雅英

     詳細を見る

    出願番号:2015153712  出願日:2015年

    出願国:国内